Request for a new Department of Dermatology

at the Michigan State University College of Human Medicine

**Submitted September 12, 2022**

**Updated October 20, 2022**

**Updated November 22, 2022**

**Note: Process for requesting establishment of a new department at MSU:**

* Dean first seeks endorsement of the request from the CAC, then Dean takes proposal to the EVP/Provost.
* EVP/Provost will send the request to Steering Committee to route through academic governance for consideration and a recommendation (e.g., University Committee on Faculty Affairs; University Committee on Graduate Studies).
* EVP/Provost makes decision to support the request or not and confers with President.
* EVP/Provost takes request and recommendation for approval to Board of Trustees.
* The Board of Trustees is required to approve the creation of any new department.

Rationale for a new Department of Dermatology

**The College of Human Medicine seeks to create a state-wide MSU department of Dermatology**. Dermatologists treat more than 3,000 conditions that affect the skin, hair, and nails. Skin diseases are especially common, affecting one in four Americans each year. The college has had a division of dermatology (the Nicholas V. Perricone, M.D., Division of Dermatology) since 2002. The division has been a successful collaboration of community clinicians and MSU scientists from a range of home departments. While successful in many domains, the division has not had the scope and scale of a department and has not been able to support clerkships for students or engage in outreach.

With the partnership of Henry Ford Health and MSU, the college has the opportunity to radically improve the educational opportunities for students as well as strengthen the basic and clinical research related to dermatology. The current Henry Ford Health (HFH) dermatologists and researchers are outstanding with a culture of caring, hard work, discovery, and patient centered outcomes. The faculty have an incredible depth to the number of subspecialties within the field of dermatology. Each of the core faculty has a few areas of subspecialty interest. This includes a group of clinically strong general dermatologists at HFH satellite clinics. The Henry Ford Department of Dermatology is a regional and national referral center for many

complex dermatologic diseases. The creation of the MSU Department of Dermatology will expand the academic reputation and opportunity for Henry Ford; MSU will advance its clinical reputation, educational opportunities for students, and scholarly opportunities for faculty and students across its system.

The existing division will continue. At this point the funding from the division is used to support research, and that will continue. No faculty are appointed in the division, and the Department of Medicine has been the administrative home of the division. The college will work with the donor and existing faculty partners before making any changes in the division.

Please see Attachment 1 – Faculty for more detail.

Within the specialty of Dermatology, the HFH program is highly sought after for resident/student rotations and is known internationally. Michigan State will immediately benefit from the unit’s national standing, excellence in training medical students/residents, and a culture of caring. Long term growth of collaborations across the MSU system will increase strength and opportunities in all missions.

The faculty of the department are highly engaged academically leading strong research, clinical, and outreach programs. The existing research teams have been very successful with two million in NIH expenditures this year. That level of funding will lead the MSU department to have a Blue Ridge Ranking in the top 20 nationally. The teams include scientists, clinicians, and students. Beyond the NIH funding the department has a strong publishing record, are recognized nationally with awards and leadership positions.

**Attachment 2** – 300+ Publications of Department faculty 2019, 2020, 2021.

**Attachment 3** – Faculty Awards and Honorifics – Including offices and roles in national organizations.

**Attachment 4** – Grants (separated into federal and non-federal grants)

A Special Focus and Strength in Diversity, Equity, and Inclusion

With the implementation of MSU-HFH partnership, the institutional leaders created the Diversity, Equity, Inclusion, and Justice Committee (DEILJ Committee). Dr. Lim, a HFH dermatologist and national leader in dermatology, is the co-chair of this important committee. The committee’s purpose is ensuring the DEIJ effort is implemented across all the five key committees (Research, Cancer, Education, Clinical and Administration). The DEIJ committee has started the planning of a Center of Excellence on Health Equity, a joint effort of HF and MSU.

Increasing diversity in the field of dermatology, is a priority of the HFH faculty. This was initially led by Dr. Henry Lim (former chair of the HFH Dept. of Dermatology) when he was the president of the American Academy of Dermatology; he continues as a leader at HFH. The faculty are

involved in diversity activities both at a program and national levels. HFH is a member of the Diversity Champion Initiative of the American Academy of Dermatology (AAD). The faculty participate in national diversity committees, including the American Academy of Dermatology Diversity Task Force, and Dr. Lim was a founding Board member of the Skin of Color Society. Several of these faculty speak regularly at annual and summer meetings of the AAD on skin of color topics and have published textbooks on Skin of Color. Dr. Lim was the co-chair of the first DEI Symposium held at the AAD in 2022.

HFH Dermatology faculty has a long-standing commitment to diversity, equity and inclusion. They were among the first in the nation that established clinical and research centers on skin of color (SOC). They embrace a culture of diversity and have diverse faculty and support staff representation to reflect the diverse patient population in Detroit. Additionally, they provide mentorship to the underrepresented in medicine residents and students. They also have multicultural dermatology clinics and perform research on topics unique to skin of color, including hair disorders, skin cancer in skin of color, vitiligo, and pigmentary disorders. The department has also funded a scholarship for underrepresented in medicine (URiM) students and award $750 to two medical students to assist with the cost of a one-month rotation in the department.

There is a Diversity Committee within the Department of Dermatology, which consists of faculty; Dr. Diane Jackson (Chair of the Diversity Committee), Dr. Raechele Gathers, Dr. Richard Huggins, Dr. David Ozog, Dr. Holly Kerr, Dr. Pranita Rambhatla, Dr. Allison Zarbo. - Residents (Dr. Lauren Seale (PGY4), Dr. Linna Guan (PGY3), Dr. Avni Patel (PGY3); Dr. Nayha Shetty (PGY2) clinical research fellows (Dr. Marissa Ceresnie (PGY2) and Dr. Jalal Maghfour (PGY2) and Research Medical Student (Brittani Jones). The committee meets several times a year to plan activities to improve recruitment, selection and retention. These activities have included implicit bias testing during interview season. They have dedicated three Grand Rounds focusing on diversity and all members of the department are encouraged to attend including faculty, residents, fellows, medical students, nurses, medical assistants, program coordinators, administrative assistants, front desk receptionists/all support staff. For the 2022-2023 academic year HFH Dermatology will be a pilot site for the American Academy of Dermatology (AAD) diversity curriculum.

HFH Dermatology program, as well as the entirety of Henry Ford Health, is committed to providing a work environment and culture that maximizes the professional growth of employees and meets the health care needs of the diverse communities that we serve. It is the policy of the program to provide equal employment opportunities to all Henry Ford Health employees and applicants for employment.

In order to achieve/ensure diversity in trainee recruitment, selection and retention faculty in the program actively emphasize and prioritize mentorship opportunities that arise with URIM applicants and current residents. Additionally, annually at the program evaluation committee (PEC) meeting, faculty reflect on GME provided diversity data of all current trainees annually.

This data is utilized to reflect and identify further opportunities to advance and increase trainee recruitment, selection and retention.

HFH dermatology program values developing and sharing best practices regarding GME Diversity and Inclusion Recruitment Strategies. All program directors and program coordinators were invited to attend a three-part series looking at the overview of diversity, equity, and inclusion strategies, holistic review processes and using the data to guide future recruitment efforts. These sessions were also recorded and housed in the CME system for future sharing and use.

URiM residency candidates are reviewed separately by key members of the Diversity Committee. In order to achieve/ensure diversity in trainee recruitment, selection and retention faculty participate in recruitment fairs and outreach programs, however, the COVID-19 pandemic has greatly impacted these opportunities. In accordance with the AAMC statement about virtual interviews, this year we will be continuing virtual interviewing. This promotes equity in the application process.

This new department will strengthen and expand the academic environment of the college and

MSU. Some of the key benefits include:

* Curricular expansion for MSU medical students interested in the field of dermatology. Currently, there are no dermatology courses or rotations. Students who want dermatology rotations take electives in the Department of Medicine. Obviously, this does not lead to a transcript that supports eventual placement in a dermatology residency program. Creation of this department will solve this problem for students. In a similar fashion, with the creation of the department, students will have the opportunity to get a “chair’s letter” as a part of their application to dermatology programs.
* Creation of additional academic homes for the expanding CHM paid and no-pay faculty (across Michigan). The college does have dermatology faculty across the state who provide elective experiences in dermatology for students. Their academic home is either in the Department of Medicine or the dean’s office, neither of which are well placed to support academic development of dermatology faculty. This department will help expand opportunities for these faculty.
* Expansion and enhancement of graduate medical education (i.e., residency and fellowship training). The college does not have a relationship with a dermatology residency, which limits opportunities for students and faculty. Creation of this department will solve this shortcoming.
* Strengthened research and clinical programs in the area of dermatology. The core of the Department of Dermatology has real research strength both with the NIH and with industry. This group of faculty will be a valuable addition to the scholarly efforts of the university and expand research opportunities for students and faculty.

* Improved MSU and CHM ranking based on increased research revenue. We believe this faculty group will be a top 20 department in NIH funding in the Blue Ridge Rankings. We also believe it will rank well across the board once recognized as an academic department.
* Help achieve 2030 university strategic goal for $1 billion in annual research expenditures
* Increase in MSU faculty honorifics. This group of faculty are well recognized internationally and will advance the university’s reputation.

Goals of the Department of Dermatology

(a) Research Mission

The department will have several research foci, supported by extramural agencies, industry and departmental funds. There is substantial success in drug discovery and skin cancer in the current dermatology division, although the home departments for those faculty are expected to stay in their current departments. We expect those faculty to help support the new department but grant and scholarship attribution will stay with their current home departments (e.g., Pharmacology and Toxicology.)

The research faculty who will populate the new department have several areas of strength. The photomedicine and photobiology unit, focusing on diseases of people of color (photoprotection, vitiligo, pigmentation, hidradenitis suppurativa), is an international leader. The dermatologic oncology unit is nationally recognized.

Immunology/cutaneous biology laboratory has a total of 8 NIH grants (4 of them RO1s); it is ranked number 1 among non -University group, and top 20 among US medical schools. The clinical trial unit is one of the most active ones in the US with over 15 current industry studies actively recruiting.

(b) Education mission

There are no other dermatology residency programs or fellowships in the CHM system. Our only residency or fellowship faculty are at Henry Ford.

Graduate Medical Education programs in dermatology:

The mission of the residency program is to train and educate residents to become local and national leaders, who excel in providing general dermatology care and with knowledge in numerous dermatology subspecialty fields, to provide patient-centered exceptional care to all

patients. The residency program respects and takes pride in the diversity, equity and inclusion of their patients and department. They promote giving back to the local and global community.

Graduate students routinely work in the extensive basic science, immunology and dermatology lab under the direction of Qing-Sheng Mi MD, PhD.

Over 60 students rotate annually for one-month blocks in the clinics with a formal didactic program, patient interaction, and examination. This is a highly sought elective with several hundred applicants for the limited spots.

With 21 residents (7 per class), 3-4 fellows, and 1-3 students, HFH dermatology department is one of the leading academic programs in the country. There are over 500 applications for 7 residency positions and 60-70 applicants are interviewed after comprehensive review of their CV’s including a separate DEIJ committee looking both for URIM candidates as well as “distance traveled”/culture of caring.

AIMS/Goals of residency

* 1. Encourage involvement with departmental, organizational, regional, and national committees and organizations.
	2. Provide training in dermatologic disease such that the resident completing the training program shall be an expert in the diseases of the hair, nail, skin and adjacent mucosa. We will provide a curriculum that is well rounded and engaging. Thediverse clinical setting provides both general dermatology and numerous subspecialty clinics.
	3. Provide training in service excellence such that the resident completing the training program shall excel at every aspect of the physician-patient relationship.
	4. Promote and nurture scientific and research endeavors such that the resident completing the training program can continue lifelong learning and the pursuit of continual self-improvement.
	5. Create a culture of giving back to Detroit/region and engaging in global health opportunities.
1. Service and outreach mission

Dermatologists around the state provide a range of outreach and community service. For this application, following examples are provided from Henry Ford Health.

About the Cabrini Clinic:

St. Frances Cabrini Clinic was established in 1950 located at 1234 Porter Street and is a ministry established by the Most Holy Trinity Catholic Church to meet the medical needs of those 19 to 64 years old that are uninsured or underinsured. The clinic assists in the primary health care

needs of the economically disadvantaged residents of Southwest Detroit and beyond. Both residents and staff provide free care at this clinic and coordinate care with other specialties, donate supplies when appropriate.

Team members further participate in free skin cancer screenings including “Melanoma Mondays” at the Cancer Center, and evaluation of staff and professional players for the Detroit Tigers and Detroit Lions.

We have an international exchange program with Dermatology Department in Bogota, Colombia. Their senior residents rotate in the HFH dermatology department and vice versa. Past comments from participants include “best month of my life” and “learning exceeding anything I could have imagined”.

(d) Clinical mission

At all locations around the state, including for dermatologists in Lansing, the clinical efforts of faculty accrue to their home clinic. As an example, Henry Ford Health dermatology has a clinical patient volume in excess of 80,000 visits per year which occur at six outpatient clinics and a surgical center (Mohs surgery). 29 staff physicians and 21 residents care for these patients. The Department provides general dermatology care for the community in addition to subspecialty clinics and is a referral center for Vitiligo, Skin Cancer, Hidradenitis Suppurativa, Scars, Complex Medical Dermatology, Psychiatric Dermatologic conditions, Skin Allergies, Photomedicine, Hair Loss, and Laser Treatment of Skin Disease. We provide the Inpatient consultations and teaching services for Dermatology at Henry Ford Hospitals in both Detroit and West Bloomfield.

Additional Goals include:

1. Development of a comprehensive skin cancer center in Detroit to care for the most complex cases in a multidisciplinary fashion. This work has started with the formation and management of cutaneous oncology tumor board which includes otolaryngology, radiation oncology, medical oncology, plastic surgery.
2. Contribute to system goal of NCI cancer center generation through additional meaningful NIH grant work.
3. With the leadership of Qing-Sheng Mi, continue to lead in basic science/immunology and biology of cutaneous diseases through one of the most cohesive/productive dermatology labs in the world. In addition to mature faculty with multiple mentees, the HFH department houses the most advanced equipment for discovery. Total equipment investment is over $4,000,000. These are “non-siloed” groups that work with other departments both within HF and externally and look to leverage commonalities between cutaneous and internal disease processes.

1. Develop imaging options for skin cancers that will reduce recurrence and lead to treatment options with lasers. With one of the only dermatology physicists in the world, Indermeet Kohli PhD, the team is currently exploring microfocused ultrasound, reflectance confocal microscopy, optical coherence tomography, and polarized devices in conjunction with lasers, working with FDA and industry in this space.
2. Through the leadership of Henry Lim MD and his outstanding early career mentees including Tasneem Mohammad MD, solidify the Division of Photomedicine with funding and faculty. Currently faculty are internationally recognized for investigator-initiated work which has profoundly impacted dermatology though understanding and use of Narrow Band UVB for psoriasis, sunscreen expertise for FDA/industry, visible light impacts on skin, and the current focus on pigmentation which is a major issue for skin of color patients.
3. Develop an “Institute for academic cosmetic medicine” for teaching and treatment of both medical and cosmetic patients. This will include treatment of scars, disfigurement, and conditions both genetic and acquired.
4. Work with insurance, industry, and philanthropy to develop self-sustaining clinics for complex medical dermatology cases which require additional time and resources.

Benefits to Michigan State University

Overall, this new Department of Dermatology will strengthen and expand the academic environment of the college and MSU. Addition of this department will allow for curricular expansion of the College of Human Medicine and create additional academic homes for the expanding CHM faculty (both paid and no-pay faculty) across the state of Michigan. The growth of the program and the faculty will bring several opportunities for strengthening and enriching educational and research activities for CHM, including: The opportunity to develop new areas of curriculum in dermatology and offer highly desirable student experiences in dermatology disciplines not currently represented in other CHM campuses. The ability to establish additional required experiences and competencies that would not be possible without the addition of qualified faculty. The enhancement of graduate medical education (dermatology residency program)) throughout our system by the addition of programs in Henry Ford that we cannot currently offer at MSU. Strengthened subspecialty research, and clinical programs that will provide the necessary platform for translational and population-based research, as well as support the supply of well- trained physicians and physician scientists to meet future recruitment needs in all of our communities across the state of Michigan.

The specific research focus in the various dermatology research areas including immunology, cancer, etc, provides new and additional research training opportunities for undergraduate, graduate and medical students in various biomedical programs at MSU. Importantly, the

research program in this department is currently funded by grants from external funding (including NIH) totaling over $2 million. Once the department is approved, it should be ranked in the top 20 of the Blue Ridge rankings.

Addition of the department to MSU will increase NIH funding (to MSU) that will undoubtedly and significantly improve MSU ranking overall. In addition, it will also help in achieving MSU’s strategic goal for reaching $ 1 billion in research expenditures by 2030. Given the success of faculty both in terms of the clinical and research missions, faculty in the Department of Dermatology have received several honors and awards and this will also significantly increase MSU faculty honorifics (another strategic goal for MSU). Lastly, CHM has an active and on-going relationship with several community partners and philanthropists. Creation of this department of dermatology and expansion of dermatology research at MSU will provide expanded opportunities for new endowments. Overall, creation of the department of dermatology in the College of Human Medicine will bring about several important benefits to the university and to the State of Michigan.

Programmatic, operational and financial considerations

Alignment with existing departments/units in CHM and MSU

Creation of this Department of Dermatology will provide research and educational collaborative opportunities across the College of Human Medicine and multiple colleges of MSU. There are already existing funding opportunities for collaborative research and education, through the Henry Ford-MSU partnership. Faculty from both existing MSU departments and Henry Ford departments will be able to apply for internal and external grant programs collaboratively that will strengthen the grant portfolio of MSU faculty and significantly increase research expenditure.

There are multiple units in the college and the university that have faculty and students who do research in the area of immunology and cancer care/prevention. Addition of the department creates new opportunities and potential collaborations for these faculty and students. There is nothing about the department that would limit the ability of other colleges or departments from hiring faculty in their respective departments and/or research programs.

Department structure

Each proposed department will be led by a department chair. Addition of this clinical subspeciality department will also be an opportunity for the state’s Medicaid uplift. We expect significant funding to come to the college through this program, and we have pledged to use this money to support scholarship, research, and education in the MSU department’s collaboration with Henry Ford. While the college could fund a few faculty

in these departments, the vast majority of the faculty will be employed by Henry Ford, and the Henry Ford chairs will do the vast majority of their faculty supervision as a Henry Ford supervisor. There will be, however, some work to be done as an MSU supervisor and as an MSU leader. With that in mind, we would like to support these chairs at 5-10% either as a dually employed faculty or leased by CHM from Henry Ford. HFH is using the lease model to support the current position as chair (Dr. Rick Leach) for Ob/Gyn at Henry Ford Health. This chair funding by MSU is essentially facilitation for partnership development and we would request access to the “mission-support” funding provided through the partnership Definitive Agreement.

Faculty appointments

Faculty will be appointed in multiple ways. Faculty that are already in the departments at Henry Ford will be appointed as no -pay faculty in one of the following tracks depending on their role and contribution to the education and research missions of the college: Prefix, non-prefix and research tracks. For these various faculty tracks, we will follow the same process we currently follow in the college. When funding is available for new MSU-based faculty positions, these will be done using existing faculty hiring processes.

In addition to clinical and non-prefixed faculty from Henry Ford Health, there will be clinical and non-prefixed faculty in the discipline joining from other communities, including Lansing and Grand Rapids. The vast majority of these faculty are engaged in elective clerkships for MS3 and MS4 students in our eight campuses across the state.

(New paragraph added in response to CAC request at their October 17, 2022 meeting). Upon establishment, new departments may initially not have voting-eligible, full-time faculty sufficient to participate as regular representatives to the CHM College Advisory Council (see CHM Bylaws Section 1.1.5.2.4. and 1.1.5.2.5. with referred definitions

1.1.1.). Departments with no eligible faculty with university level voting rights will send a CAC representative who will be granted voice but no vote, until such a time as they have eligible faculty to serve. It is expected that full-time MSU faculty will be added over time through enhanced Medicaid funding returned to MSU as well as new Henry Ford Health – MSU Health Science Center (HSC) funding. The college expects there will be 20 -40 hires through these mechanisms. Priority will be given to addition and retention of at least two eligible faculty with university level voting rights (see CHM Bylaws Section 3.1.2.3.) within each department.

Chair selection

With creation of the Department of Dermatology, the dean will first appoint an interim chair. After initial establishment of the department with faculty appointments, the dean (or designate) will work with the faculty and the interim chair to develop departmental bylaws that will go through appropriate approvals at the college and university levels. Once the bylaws are in place, the dean will work with the department to formulate a

search for a founding chair and subsequent chairs using existing university guidelines. Depending on the circumstances of the department and the faculty some of these searches will be national and some may be internal.

Department operations, governance, bylaws and RPT criteria

The department will operate in a manner consistent with other departments in the College of Human Medicine and will adopt a shared governance model. Shared governance with the existing faculty, staff, and students will follow the MSU Academic Governance policies.

The interim chair will work with the dean to appoint a bylaws committee. The bylaws committee will include five faculty members and one outside faculty member with expertise in reviewing bylaws. Bylaws will be voted on and approved by a majority of department faculty before ratification. A scaffolding of the bylaws and major sections have already been identified and minimally will include sections on organization; governance; committees; RPT; grievances and complaints; and faculty (e.g., composition, meetings, appointment, reappointment, promotion, tenure, responsibilities, etc.)

Reappointment, promotion, and tenure criteria will align with the College of Human Medicine criteria which are written, well-specified, and available on the [CHM Faculty](https://humanmedicine.msu.edu/faculty-staff/faculty-affairs/promotion/index.html) [Affairs website](https://humanmedicine.msu.edu/faculty-staff/faculty-affairs/promotion/index.html) under the ‘Promotion and Tenure’ tab. An RPT committee will be established within the Department of Dermatology to work with the chair to manage the RPT processes.

Department Finance

Current Funding Status, Allocation, and Reserve Funds

The college is proposing a series of new departments based on faculty joining MSU and CHM from Henry Ford Health that complement the work of the college and university and highlight unique strengths of the HFHS faculty. The health system, college, and partnership will provide support for the faculty and administration of the department. Most support will be in the form of faculty salary, which will come from the medical group within the health system. The Office of Health Sciences has committed financial resources from the overall MSU-HFHS partnership effort to support creation of departments. Discretionary funding will be used to support a small part of the salary and an administrative increment for the chair’s MSU employment.

As the department integrates into the college, the department will enter into the Medicaid uplift program providing additional support for the department and funding additional MSU faculty in the department.

The department will accrue reserves and start-up funds as all other departments in the college do.

Projected financial needs and how financial obligations of the department, including administrative costs will be met

Projected financial needs are centered around ongoing recruitment and retention of high-caliber faculty to support our education, research, and service missions. The college will direct Medicaid uplift derived from HFH to use in the departments based out of HFH to fund new positions and programs in the departments and college.

The current college allocation and reserve funds more than meet the projected financial needs and financial obligations of the proposed department, including administrative costs.

The college and the department expect additional philanthropy as well.

Oversight of the curriculum

The department will participate in the college’s educational programs as all other departments do. Electives and rotations in the MD curriculum will be approved and supervised by the CHM MD Curriculum committee. All other courses and educational programs will be reviewed by the college’s Graduate Studies curriculum committee. The department’s residency and fellowship programs operate with oversight from the departmental residency committees consistent with the ACGME accreditation of Henry Ford Health. The department will have a clerkship committee to oversee its medical student and any other educational programs not a part of the residency programs.

Evaluation of departmental effectiveness

The new department will enter the standardized process for assessing departmental effectiveness consistent with all departments at CHM. There will be the usual five-year department and chair review as well as annual chair reviews.

Systems for Effectiveness of Departmental Operations

For the HFH faculty complete summaries of the programs below will be available to the college on request. For the current period all metrics have been met or exceeded. The unit evaluations are particularly strong in the training domains. Engagement is high despite challenging environment for productivity and patient access among Dermatology faculty. We currently rank 7th of 42 surveyed departments/divisions at HF at the 81%tile nationally (Press Ganey 2022 data).

* Focused Professional Performance Evaluations (FPPE – First two years of practice and/or remediation, bi-annual))
* Ongoing Professional Performance Evaluations (OPPE – bi-annual)
* Financial Reviews and Chair Performance reviews (bi-annual)
* Peer Reviews (ad hoc and bi-annual)
* Annual HFH resident survey (fall)
* Annual ACGME Resident Survey (spring)
* Annual ACGME Faculty Survey
* Annual Program Evaluation by the program. Reviewed by the GME annually in the fall.
* Semi Annual Faculty Evaluations by the residents
* Annual Faculty Evaluations of the Program
* Webads- Annual report to ACGME
* Med Hub – Resident and faculty evaluation
* Ape – Annual Program Evaluation and meeting with entire teaching faculty and all residents from each year.
* CCC meeting – All core teaching faculty evaluate residents

Systems for Effectiveness of Residency Teaching Program

The Dermatology Residency Program at Henry Ford Hospital was established in 1954. The program offers exceptional clinical training with exposure to a wide diversity of diseases in multiple skin types. We offer a three- year program (PGY-2 through PGY-4), which begins after the successful completion of a PGY-1 year. For over eight years, the dermatology residency has had continued accreditation by the ACGME with no citations. The program has 21 residents total and a 100% first time boards pass rate for over 10 years. Dr. Holly Kerr is the program director (PD), Dr. Laurie Kohen is the associate PD, and Dr. Pranita Rambhatla is the assistant PD.

Clarence S. Livingood Clinical Research Fellowship and the Henry W. Lim Photomedicine Research Fellowship are non-accredited one-year fellowships. Applicants who have completed PGY-1 training and are interested in reapplying for a dermatology residency are preferred. They work with the Investigator Initiated Studies Unit that focuses on photomedicine, follicular

and pigmentation disorders, lasers, skin cancer and photo protection. The unit’s efforts involve Department Chair, Dr. David Ozog, Chair Emeritus Dr. Henry W. Lim, with the oversight of Fellowship PD, Dr. Tasneem Mohammad and associate PD Dr. Kohli. Drs. Iltefat Hamzavi, Richard Huggins and Tasneem Mohammad are experts in vitiligo, hidradenitis suppurativa, photomedicine. Indermeet Kohli, PhD, staff physicist, and one of few physicists on staff in a dermatology department, providing expert mentorship on the application of physics and imaging in dermatology.

Edward A. Krull Cutaneous Oncology Fellowship is a one-year non-accredited fellowship. Applicants who have completed dermatology training and are interested in applying for a Mohs Micrographic Surgery and Cutaneous Oncology Fellowship are preferred. The fellowship presents an opportunity to learn the latest information about prevention, diagnosis, treatment and management for patients with melanoma and other skin cancers. Fellows will receive training at the new, state- of-the -art Cancer Center in the multidisciplinary management of patients with skin cancers using treatment modalities such as surgical management, targeted therapy, immunotherapy, chemotherapy, and radiation. Dr. Molly Powers, a board-certified Mohs surgeons, is the program director.

The Pediatric Dermatology Fellowship, is a one-year, American Board of Dermatology approved fellowship. We are currently seeking ACGME accreditation for this fellowship. The fellowship program is open to American Board of Dermatology eligible applicants. The pediatric dermatology fellow has access to tremendous educational, teaching, clinical, and research opportunities.

Existing system for annual performance reviews of faculty and staff:

Faculty reviews are performed bi-annually through Focused Professional Performance Evaluations (FPPE – First two years of practice and/or remediation) as well as Ongoing Professional Performance Evaluations (OPPE). These are done in person with written feedback/agreement on personal and professional performance goals. Each team member’s patient satisfaction comments and r metrics of professionalism including mandatory modules in Henry Ford University related to safety, patient care, and diversity are reviewed. Financial performance and metrics are also reviewed As well as CME and participation in grand rounds and other departmental initiatives. Additionally, system engagement surveys are conducted and reviewed at faculty meetings which occur monthly.

Educator Staff Evaluation Reviews

The teaching performance of core faculty is assessed twice per year by the residents. This anonymous feedback is reviewed with the core faculty at their ongoing professional practice evaluation (OPPE) with the chair. When goal setting for the next 6 months, the core faculty are

asked to identify three area for continuous growth, one which usually comes from resident feedback.

Faculty development is a priority for the department and annually we arrange departmental faculty development sessions. For example, during the 2021-2022 academic year, core faculty participated in the High Impact Educational Endorsement (HIEE) program. Grounded in adult learning theory and research, the program promotes innovative, collaborative, and equitable practices to create lifelong learners and leaders in medical education. This five-part series included education about Instructional Practices and Engaging Learners, Instruction & Assessment Strategies, Giving and Receiving Feedback, Cultural Humility and Safe Learning, as well as Mentorship & Coaching.

The Association of the Professors of Dermatology (APD) is an organization of leading educators in dermatology and all key core faculty are members. The APDs aims to advance educational and patient care standards, help develop support strategies for academic dermatology and provides ethical leadership in the dermatology community. The annual meeting is attended by the chair, program director, associate and assistant program director, director of Mohs surgery and other core faculty.

**Success of outreach and community engagement programs**

St. Frances Cabrini Clinic was established in 1950 located at 1234 Porter Street and is a ministry established by the Most Holy Trinity Catholic Church to meet the medical needs of those 19 to 64 years old that are uninsured or underinsured. The clinic assists in the primary health care needs of the economically disadvantaged residents of Southwest Detroit and beyond. For over 65 years. Detroit’s St. Frances Cabrini Clinic has provided free health care to low-income, vulnerable patients in Michigan’s largest city. As the oldest free clinic in the US those years have taught us a lot about what it means to be healthy, the value of treatment at a community level and the importance of ongoing wellness education. For over 10 years, the department of Dermatology has volunteered once a month at the Cabrini Clinic in Detroit, MI. The Cabrini Clinic is America’s oldest free clinic. Once a month on a Tuesday evening one senior staff, two residents and occasionally medical student rotators will care for dermatology patients. We receive consistent feedback for the program and individual patients about impactful changes in diagnosis and access.

Annually, faculty organize free skin cancer screenings in association with the American Academy of Dermatology. These are usually around Melanoma Monday (first Monday of May). In addition, faculty have provided annual free skin cancer screening for all employees of the Detroit Tigers establishment. Both senior staff and residents volunteer their time. Faculty routinely identify skin cancers in these programs which are treated earlier with potential life-saving benefit.

Overall department effectiveness will include measures of programs, faculty, students, staff, and community partners across all missions. Minimum measures will include:

* Faculty success – time in rank, tenure, promotion, research grants/awards.
* Student success – student evaluations from elective experiences, resident/fellow completion rate, program satisfaction.
* Staff success – retention, performance evaluations, staff feedback.
* Education/Curriculum success – continued growth, expansion, and impact.
* Financial performance based on college funding formulas, and reserve analysis.
* Outreach/engagement/service success – percentage of funds deployed to community, annual feedback from community stakeholders, faculty, and staff engagement in service work.

Assurances

For the university and college, the creation of this department will help solidify and expand the scholarly opportunities for students and faculty across the institution. With the addition of the department to MSU, it is expected that the unit will grow, adding to NIH funding in support of AAU metrics and building on the reputation of the existing faculty and programming.

The leadership of the college has discussed the creation of the department with related departments and units including meetings with leadership and faculty.

Many people across the university do work related to immunology and cancer care and treatment, just as many people across the university do work related to medicine. The existence of the College of Human Medicine does not limit the scholarly opportunities of others in the university, and this department will not change or limit the activity of faculty interested in these research areas across the institution. In fact, the success and expansion of this department increases opportunities for all.

**Distribution of proposal for endorsement, assurances, or concerns:**

(All communication by email unless otherwise indicated)

Dean Amalfitano (September 9, 2022) See Attachment 5

Chair Rayamajhi (September 9, 2022) Supports the proposal, especially given the support of the current division.

Chair Dorrance (September 9, 2022)

**College Advisory Council Summary**

* Recommendation/endorsement

The CHM CAC unanimously endorsed the proposal for a new Department of Dermatology on November 21, 2022.

**Attachment 1 - Faculty**

1. *David M. Ozog, M.D. FACMS., Chairman, Mohs/dermato-oncology/surgeon, Scar clinic Director, Laser, Imaging*
* University of Rochester School of Medicine, NY
* Fellowship in Mohs, Procedural and Cosmetic Dermatology, CA
* Henry Ford Hospital, Dermatology Residency, MI
1. *Henry W. Lim, M.D., Former Chairman, Photomedicine, Vitiligo, Cutaneous T Cell Lymphoma (CTCL), Complex Medical Dermatology*
* State University of New York, Medical Education, NY
* SUNY Downstate Health Sciences University, NY
* New York University School of Medicine, Dermatology, NY
* Bronx Municipal Hospital Center, Pediatrics, NY
1. *Holly Kerr, M.D., Program Director of the Dermatology Residency Program, Vice Chair Department. Patch Test clinic, Transplant Dermatology and Integrative Dermatology (combined clinic with Psychiatry)*
* University of Ottawa, Canada
* Henry Ford Hospital, Dermatology Residency, MI
1. *Anna Axelson, M.D., Oncodermatology, Transplant Dermatology*

• Emory University School of Medicine, GA

• Stanford University Hospital, Dermatology Residency, CA

1. *Kim Baker, P.A. Clinical Care/Clinical Trials*
* Maryville University, Nurse Practitioner, MO
* Wayne State University School of Medicine, Nursing, MI

*6.* *Mark Balle, M.D., Director of Mohs Surgery*

* Wayne State University School of Medicine, MI
* Henry Ford Hospital, Dermatology Residency, MI
1. *Alison Tisack Boucher, M.D., Director of Cosmetic Dermatology, Clerkship Director*

• Wayne State University School of Medicine, MI

• Henry Ford Hospital, Dermatology Residency, MI

1. *Marsha Chaffins, M.D., Co- Director Dermatopathology*

• University of Kentucky School of Medicine, KY

• Henry Ford Hospital, Dermatology Residency, MI

• University of Texas, Dermatopathology Fellowship, TX

1. *Thomas Downham, M.D., General Dermatology*
* University of Michigan School of Medicine, MI
* Wayne State University, Dermatology Residency, MI
1. *Ben Friedman, M.D., Co-Director Dermatopathology, Cutaneous Lymphoma*

• Perelman School of Medicine - University of Pennsylvania, PA

• Henry Ford Hospital, Dermatology Residency, MI

• Thomas Jefferson University Hospital, Dermatopathology Fellowship, PA

1. *Raechele Gathers, M.D., Multicultural Dermatology*
* University of Michigan School of Medicine, MI
* Henry Ford Hospital, Dermatology Residency, MI
1. *Iltefat Hamzavi, M.D., Follicular Disorders Clinic, Vitiligo, Melanocyte Keratinocyte Transplant*
* University of Michigan School of Medicine, MI
* Wayne State University School of Medicine, Dermatology Residency, MI
* University of British Columbia, Photoderm & Lasers Fellowship
1. *Richard Huggins, M.D., Division Head Ford Road. Follicular Disorders Clinic, Hidradenitis Suppurativa, Vitiligo, Melanocyte Keratinocyte Transplant*
* Rutgers New Jersey Medical School, NJ
* Henry Ford Hospital, Dermatology Residency, MI
* Henry Ford Hospital, Dermatology Research Fellowship, MI
* Northwestern University Feinberg School of Medicine, Dermatology Research Fellowship, IL
1. *Diane M. Jackson-Richards, M.D., Chair of the Department of Dermatology Diversity Committee, Multicultural Dermatology*
* University of Michigan School of Medicine, MI
* University of Michigan, Dermatology Residency, MI

*15. Marla Jahnke, M.D., Pediatric Dermatologist*

* Wayne State University School of Medicine, MI
* Wayne State University School of Medicine, Dermatology Residency, MI
* Henry Ford Hospital, Pediatric Dermatology Fellowship, MI

*16. Amin Jiang, PhD, Assoc. Scientist*

* University of Washington, Microbiology, WA
* Cancer Research Institute, Research Fellowship, NY
1. *Lydia Juzych, M.D., Division Head Troy, General Dermatology*

• Wayne State University School of Medicine, MI

• Henry Ford Hospital, Dermatology Residency, MI,

1. *Laurie Kohen, M.D., Associate Program Director of the Dermatology Residency Program. Pigmented Lesion clinic*
* University of Michigan School of Medicine, MI
* Henry Ford Hospital, Dermatology Residency,MI
1. *Indermeet Kohli, PhD, Physicist, Associate Program Director for the Lim and Livingood Research Fellowships, Imaging and photomedicine research*
* Wayne State University School of Medicine, MI
1. *Sasank Konda, M.D., Inpatient Dermatology, Complex Medical Dermatology*

• University of Chicago Pritzker School of Medicine, IL

• Henry Ford Hospital, Dermatology Residency, MI

1. *Jungho Kwon, M.D., General Dermatology*
* University of California School of Medicine, CA
* Henry Ford Hospital, Dermatology Residency, MI
1. *Natalie Matthews, M.D. Anticipated Oct 2022. Pigmented Lesion clinic*

• Warren Alpert Medical School of Brown University, Providence RI

• University of Michigan, Dermatology Residency, MI

1. *Qing-Sheng Mi, M.D, PhD. Division Head Immunology Rsch. Director of Basic Science research Department of Dermatology*
* China Medical University, China
* Taishan Medical University, China
* Taishan Medical University, Dermatology Residency, China
1. *Tasneem Mohammad, M.D., Program Director for the Lim and Livingood Research Fellowships, Pigmentary Disorders Clinic, Photomedicine including EPP clinic, Follicular Disorders clinic*
* University of Toledo College of Medicine, OH
* Henry Ford Hospital, Dermatology Residency, MI
* Henry Ford Hospital, Dermatology Research Fellowship, MI
1. *Molly Powers, M.D. Program Director for the Edward A. Krull Cutaneous Oncology Fellowship, Mohs Surgeon*
* Loyola University Stritch School of Medicine, IL
* Henry Ford Hospital, Dermatology Residency, MI
* Zitelli and Brodland Clinic, Dermatology Mohs Surgery Fellowship, PA
1. *Pranita Rambhatla, M.D. Assistant Program Director of the Dermatology Residency Program. Rheumatology- Dermatology Combined Clinic*
* Wayne State University School of Medicine, MI
	+ New Henry Ford Hospital, Dermatology Residency, MI

*27. Teresa Romano, M.D., General Dermatology*

* University of Western Ontario - Faculty of Medicine, ON, Canada
* Henry Ford Hospital, Dermatology Residency, MI
1. *Tor Shwayder, M.D., Program Director for the anticipated Pediatric Dermatology Fellowship, Pediatric Dermatology*
* University of Michigan, School of Medicine, MI
* Strong Memorial Hospital, Dermatology Residency, NY
* University of Michigan, Pediatric Fellowship, MI

1. *Linda Stein, M.D., Division Head West Bloomfield Clinic, General Dermatology, Research Director of Clinical Trials, AAD Vice-President 2022-23.*
* University of Pennsylvania, School of Medicine, PA
* Henry Ford Hospital, Dermatology Residency, MI

*30. Allison Zarbo, M.D., Pediatric Dermatologist*

* Wayne State University School of Medicine, MI
* Henry Ford Hospital, Dermatology Residency, MI
* Henry Ford Hospital, Dermatology Pediatric Fellowship, MI

*31. Cristina de Guzman Strong, PhD., Assoc. Scientist*

* University of Alabama Hospital at Birmingham, Genetics, AL
* National Institutes of Health, NICHD, Research Fellowship, MD
1. *Jesse Veenstra, M.D., PhD., Complex medical dermatology, Immunobullous disorders, Cancer research*
* Wayne State University School of Medicine, MI
* Henry Ford Hospital, Dermatology Residency, MI

*33. Najat Watch, PA, Clinical*

* Cleveland State University, Physician Assistant, OH
1. *Li Zhou, PhD., M.S., Assoc. Scientist*
	* Johns Hopkins Hospital, Research, MD
	* Shanghai Medical University, China
	* Taishan Medical University, China
	* John P. Robarts Research Institute, Research Fellowship, ON
	* National Institute on Aging, Research Fellowship, MD

**Number of total faculty** – 35

**Number of research faculty** - 12

**Number of clinical faculty** - 30

**Distribution of rank at Henry Ford/WSU** -

|  |  |
| --- | --- |
| Ozog, David, Chairperson | Clinical Assistant Professor |
|  |  |
| Lim, Henry, Chairperson Emeritus | Professor, FTA Clinician Educator |
|  |  |
| Balle, Mark | Clinical Associate Professor |
|  |  |
| Chaffins, Marsha | Clinical Associate Professor |
|  |  |
| Downham, Thomas | Clinical Professor |
|  |  |
| Friedman, Ben | Clinical Assistant Professor |
|  |  |
| Hamzavi, Iltefat | Clinical Associate Professor |
|  |  |
| Jahnke, Marla | Clinical Assistant Professor |
|  |  |
| Kerr, Holly | Clinical Assistant Professor |
|  |  |
| Mi, Qing-Sheng | Adjunct Professor |
|  |  |
| Rambhatla, Pranita | Clinical Assistant Professor |
|  |  |
| Stein Gold, Linda | Clinical Associate Professor |
|  |  |

**Demographics (for DEIJ purpose)**

4 African American

9 Asian

3 Middle Eastern

19 White

1. Male
2. Female

**Attachment 2 – Publications of department faculty for the last three years**

**2021 Dermatology Publications**

**Awosika O, Grayson C, Pritchett E.** Global Initiatives in Dermatology and Education. J Am Acad

Dermatol. In Review:

PMID: None

Pub: Apr 2021

**Awosika O**, Eleryan MG, and Soleymani T. Reply to the editor regarding Local recurrence of clinically observed basal cell carcinomas following complete saucerization or punch removal with negative margins: Retrospective case series from 2010 to 2020. J Am Acad Dermatol 2021; Epub ahead of print.

PMID: 34274411 Epub: July 2021

Zia S, Shaw B, **Chapman S**, and **Friedman BJ**. An atypical chondroid syringoma with malignant degeneration: utility of comparative genomic hybridization in confirming the diagnosis. *J Cutan Pathol* 2021.

PMID: 33470448. Epub: Jan 2021

**Chapman S, Kwa M, Gold LS, and Lim HW**. Janus kinase inhibitors in dermatology: Part I. A

comprehensive review. J Am Acad Dermatol 2021; Epub ahead of print. PMID: 34246698

Epub: July 2021

**Chapman S, Gold LS, and Lim HW.** Janus kinase inhibitors in dermatology: Part II. A comprehensive

review. J Am Acad Dermatol 2021; Epub ahead of print. PMID: 34228996

Epub: July 2021

Umeh ON, Beekman R, D'sa H, and **Friedman BJ**. An Elderly Male With Progressive Nail Atrophy:Answer. Am J Dermatopathol 2021; 43(2):152-153.

PMID: 33492842 Pub: Feb. 2021

**Friedman BJ**. Pitfall regarding expression of ETS-related gene (ERG) in fibrohistiocytic neoplasms. J Cutan Pathol 2021.

PMID: 33837979

Epub: April 2021

**Friedman BJ**, Robinson G, and Kohen L. Dermoscopic Features of Spitz Tumor With LMNA-NTRK1

Fusion. Dermatol Pract Concept 2021; 11(1):e2020101. PMID: 33354405

Epub: Dec. 2020 Pub. Jan. 2021

**Guan L**, **Lim HW, Mohammad T.**

Clin Dermatol. 2021 Aug 13;1-10.

Pub: Aug 2021

Sunscreens and Photoaging: A Review of Current Literature. Am J PMID:34387824

Collier EK, Price KN, Grogan T, Fernandez JM, Seivright JR, Alhusayen R, Alavi A, **Hamzavi IH**, LowesMA, Porter MJ, Shi VY, and Hsiao JL. Provider perspectives on the management of hidradenitis suppurativa in pregnancy – A survey study. International Journal of Women's Dermatology 2021.

PMID: Epub Jan. 2021

Garg A, Malviya N, Strunk A, Wright S, Alavi A, Alhusayen R, Alikhan A, Daveluy SD, Delorme I, Goldfarb N, Gulliver W, **Hamzavi I**, Jaleel T, Kimball AB, Kirby JS, Kirchhof Md MG, Lester J, Lev-Tov H, Lowes MA, Micheletti R, Orenstein LA, Piguet V, Sayed C, Tan J, and Naik HB. Comorbidity screening in Hidradenitis Suppurativa: evidence-based recommendations from the US and Canadian Hidradenitis Suppurativa Foundations. *J Am Acad Dermatol* 2021.

PMID: 33493574 Epub: Jan. 2021

Austin E, Geisler AN, Nguyen J, Kohli I, **Hamzavi I**, **Lim HW**, and Jagdeo J. Visible Light Part I. Properties and Cutaneous Effects of Visible Light. *J Am Acad Dermatol* 2021;

PMID:33640508 EPub: Feb. 2021

Geisler AN, Austin E, Nguyen J, **Hamzavi I**, Jagdeo J, and **Lim HW**. Visible Light Part II. Photoprotection against visible and ultraviolet light. J Am Acad Dermatol 2021.

PMID: 33640513 Epub: Feb. 2021

Ju HJ, Bae JM, Lee RW, Kim SH, Parsad D, Pourang A, **Hamzavi I**, Shourick J, and Ezzedine K. Surgical Interventions for Patients With Vitiligo: A Systematic Review and Meta-analysis. *JAMA Dermatol* 2021

PMID: 33595599 Epub: Feb. 2021

Price KN, Collier EK, Grogan T, Fernandez JM, Alhusayen R, Alavi A, **Hamzavi IH**, Lowes MA, Porter MJ, Hsiao JL, and Shi VY. Physician perspectives on complementary and alternative medicine in hidradenitis suppurativa. *Dermatol Ther* 2021;

PMID: 33547869 Epub: Feb 2021

Rodrigues M, Pandya AG, **Hamzavi I,** Ezzedine K, Bekkenk MW, and Harris JE. Treatment recommendations for patients with vitiligo during COVID-19. Australas J Dermatol 2021.

PMID: 34028796. EPub: May 2021

Gold DA, Nicholson C, Jacobsen G, and **Hamzavi IH.** International Classification of Diseases-based analysis is inaccurate in assessing the prevalence of inflammatory bowel disease in patients with hidradenitis suppurativa. J Am Acad Dermatol 2021; Epub ahead of print.

PMID: 34092407 Pub: June 2021

**Hamzavi I** , Rosmarin D, Harris JE, Pandya AG, Lebwohl M, Gottlieb AB, Butler K, Kuo FI, Sun K, and Grimes P. Efficacy of Ruxolitinib Cream in Vitiligo by Patient Characteristics and Affected Body Areas: Descriptive Subgroup Analyses From a Phase 2, Randomized, Double-Blind Trial. J Am Acad Dermatol 2021;

PMID: 34089797 EPub: June 2021

Collier EK, Price KN, Grogan T, Fernandez JM, Seivright JR, Alhusayen R, Alavi A, **Hamzavi IH,** Lowes MA, Porter MJ, Shi VY, and Hsiao JL. Provider perspectives on the management of hidradenitis suppurativa in pregnancy – A survey study. International Journal of Women's Dermatology 2021; 7(3):346-348.

PMID: Not assigned Pub:

Osto, M, **Hamzavi, IH**, Lim, HW, Kohli, I. Individual Typology Angle Should be Used as a Standard for Skin Type Classification in Photobiologic Studies. Submitted for publication. 2021

PMID: Pub:

Pourang A, Dourra M, Ezekwe N, Kohli I, **Hamzavi I,** and **Lim HW**. The potential effect of Polypodium leucotomos extract on ultraviolet- and visible light-induced photoaging. Photochem Photobiol Sci 2021; Epub ahead of print.

PMID: 34449075 Epub: Aug. 2021

Rehman R, Chabaan A, **Hamzavi I,** Fahs F, and **Mohammad TF**. The Etiquettes of Hijab:

Recommendations to Improve Care in Dermatology Clinics. Br J Dermatol 2021; Epub ahead of print.

PMID: 34350980 Pub: Aug. 2021

Pourang A, Tisack A, Ezekwe N, Torres AE, Kohli I, **Hamzavi IH, and Lim HW**. The Effects of Visible Light on Mechanisms of Skin Photoaging. Photodermatol Photoimmunol Photomed 2021;

PMID: 34585779 Epub ahead of print.

Thompson AM, Fernandez JM, Shih T, **Hamzavi I**, Hsiao JL, and Shi VY. Improving hidradenitis suppurativa patient education using written action plan: a randomized controlled trial. J Dermatolog Treat 2021;1-3. Epub ahead of print.

PMID: 34579620. Epub: Sept. 2021

Elbuluk N, Grimes P, Chien A, **Hamzavi I**, Alexis A, Taylor S, Gonzalez N, Weiss J, Desai SR, and Kang S. The Pathogenesis and Management of Acne-Induced Post-inflammatory Hyperpigmentation. Am J

Clin Dermatol 2021; Epub ahead of print. PMID: 34468934 EPub: Sept. 2021

Alavi A, Baradaran S, Mathias SD, Colwell HH, Song M, **Hamzavi IH**, and Han C. Development of a Patient-Reported Outcome Questionnaire to Assess Signs and Symptoms of Hidradenitis Suppurativa: The Hidradenitis Suppurativa Symptom Diary (HSSD). J Am Acad Dermatol 2021; Epub ahead of print.

PMID: 34808326. EPub: Nov 2021

Krueger L, Saizan AL, Meehan SA, Ezzedine K, Hamzavi I, and Elbuluk N. Seborrheic macular hypopigmentation: a case series proposing a new pigmentary disorder. J Eur Acad Dermatol Venereol 2021; Epub ahead of print.

PMID: 34927764

Smith Z, Wang J,

and Quality Life.

PMID: 34076392

Pub. Dec. 2021

**Huggins R**., et al. A Multi-Centered Case-Control Study of Vitiligo Support Groups J Drugs Dermatol. June 2021

Pub. June 2021

Phillips GS, Huang A, Augsburger BD, Kaplan L, Peoples K, Bruckner AL, Khuu P, Tang JY, LaraCorrales I, Pope E, Wiss K, Levin LE, Morel KD, Hook KP, Paller AS, Eichenfield LF, McCuaig CC, Powell J, Castelo-Soccio L, Levy ML, Price HN, Schachner LA, Browning JC, **Jahnke M, Shwayder T**, Bayliss S, Lucky AW, and Glick SA. A retrospective analysis of diagnostic testing in a large North American cohort of patients with epidermolysis bullosa. J Am Acad Dermatol 2021; Epub ahead of print. PMID: 34634382

Pub: Oct. 2021

**Jahnke MN**, O'Haver J, Gupta D, Hawryluk EB, Finelt N, Kruse L, Jen M, Horii KA, Frieden IJ, Price H, and Coughlin CC. Care of Congenital Melanocytic Nevi in Newborns and Infants: Review and Management Recommendations. Pediatrics 2021; E

PMID: 34845496 Epub ahead of Print

**Jiang AJ**, Soon SL, Rullan P, Brody H, Lee KC. Chemical peels as field therapy for actinic keratoses: A systematic review. Derm Surg.

PMID: 34238790 Pub. Jan 2021

**Ko D, Lyons AB, Kohli** I, Narla S, Torres AE, Miller A, **Ozog D, Hamzavi I, and Lim HW.** The value of photomedicine in a global health crisis: Utilizing ultraviolet C to decontaminate N95 respirators during the COVID-19 pandemic. Photodermatol Photoimmunol Photomed 2021; Epub ahead of print.

PMID: 34467568 Epub: Sept. 2021

**Kolli SS**, Feldman SR, and Huang WW. The dermatology residency application process. Dermatol Online J 2021; 26(12).

PMID: 33423419 Pub: Jan. 2021

**Kurland E, Friedman BJ, Rambhatla P**.Fulminant Hemorrhagic Bullae of the Upper Extremities Arising in the Setting of IV Placement During Severe COVID-19 Infection: Observations From a Major Consultative Practice. Cutis 2021 July;108(1)E31-E33.

PMID: 3439730 Pub: July 2021

Chapman S, **Kwa M, Stein Gold L, Lim, H**. Janus Kinase inhibitors in dermatology: Part I. A

comprehensive review. J AAD 2021 July 8:S0190-9622(21)-2-71-5

PMID: 34246698 EPub:

Kwa MC, and Lim HW. Commentary on: "Oxybenzone and pregnancy: Time for more research and patient education". J Am Acad Dermatol 2021; Epub ahead of print.

PMID: 34920030 Pub: Dec. 2021

McMahon DE, Gallman AE, Hruza GJ, Rosenbach M, Lipoff JB, Desai SR, French LE, **Lim H**, Cyster JG, Fox LP, Fassett MS, and Freeman EE. Long COVID in the skin: a registry analysis of COVID-19 dermatological duration. *Lancet Infect Dis* 2021.

PMID: 33460566 Epub: Jan. 2021

Freeman EE, McMahon DE, Lipoff JB, Rosenbach M, Kovarik C, Desai SR, Harp J, Takeshita J, French LE, **Lim HW**, Thiers BH, Hruza GJ, and Fox LP. The spectrum of COVID -19-associated dermatologicmanifestations: An international registry of 716 patients from 31 countries. *J Am Acad Dermatol* 2020;83(4):1118-1129.

PMID: 32622888 EPub:

Freeman EE, McMahon DE, Lipoff JB, Rosenbach M, Desai SR, Fassett M, French LE, **Lim HW**, Hruza GJ, and Fox LP. Cold and COVID: Recurrent Pernio during the COVID-19 Pandemic. Br J Dermatol 2021;

PMID: 33657646 Epub: March 2021

Passeron T, **Lim HW,** Goh CL, Kang HY, Ly F, Morita A, Ocampo Candiani J, Puig S, Schalka S, Wei L, Dréno B, and Krutmann J. Photoprotection according to skin phototype and dermatoses: Practical recommendations from an expert panel. J Eur Acad Dermatol Venereol 2021; Epub ahead of print.

PMID: 33764577 Epub: March 2021

Freeman EE, McMahon DE, Lipoff JB, Rosenbach M, Desai SR, Fassett M, French LE, **Lim HW**, Hruza GJ, and Fox LP. Cold and COVID: Recurrent Pernio during the COVID-19 Pandemic. Br J Dermatol 2021;

PMID: 33657646 Epub. March 2021

McMahon DE, Amerson E, Rosenbach M, Lipoff JB, Moustafa D, Tyagi A, Desai SR, French LE, **Lim HW**, Thiers BH, Hruza GJ, Blumenthal KG, Fox LP, and Freeman EE. Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: A registry-based study of 414 cases. J Am Acad Dermatol 2021; Epub ahead of print.

PMID: 33838206 Pub: April 2021

Boothby-Shoemaker W, **Lim HW, Kohli I, and Ozog DM.** Changes in Google search for "sunburn" during the COVID-19 pandemic. Photodermatol Photoimmunol Photomed 2021.

PMID: 33830570. EPub: May 2021

Granger C, Ong G, Andres P, Trullàs C, Hosenally M, Lai W, Liu W, Krutmann J, Passeron T, and **Lim HW**. Outdoor Sunscreen Testing with High-intensity Solar Exposure in a Chinese and CaucasianPopulation. Photodermatol Photoimmunol Photomed 2021.

PMID: 34157168 EPub: June 2021

**Lim HW**, Kohli I, Granger C, Trullàs C, Piquero-Casals J, Narda M, Masson P, Krutmann J, and Passeron T. Photoprotection of the Skin from Visible Light‒Induced Pigmentation: Current Testing Methods and Proposed Harmonization. J Invest Dermatol 2021;

PMID: 34112516. Epub: June 2021

**Lim HW,** Feldman SR, Van Voorhees AS, and Gelfand JM. Response to Implementation of Phototherapy Guidelines during Pandemic. J Am Acad Dermatol 2021.

PMID: 34403713 Epub: August 2021

Fathy RA, McMahon DE, Lee C, Chamberlin GC, Rosenbach M, Lipoff JB, Tyagi A, Desai SR, French LE**, Lim HW**, Thiers BH, Hruza GJ, Fassett M, Fox LP, Greenberg HL, Blumenthal K, and Freeman EE.Varicella Zoster and Herpes Simplex Virus Reactivation Post-COVID-19 Vaccination: A Review of 40 Cases in an International Dermatology Registry. J Eur Acad Dermatol Venereol 2021; Epub ahead of print.

PMID: 34487581 Epub: Sept. 2021

**Lim, HW, Mohammad,** TF, Wang, SQ. FDA Proposed Sunscreen Final Administrative Order: How does it affect sunscreens in the United States? J Am Acad Dermatol.

PMID: 34606770 Pub: Oct. 2021

Lopez S, Lourido JO, **Lim HW**, Ferguson NN, Pandya AG, and Vasquez R. The call to action to increase racial and ethnic diversity in dermatology: A retrospective, cross-sectional study to monitor progress. J Am Acad Dermatol 2021.

PMID: 34678231 EPub: Oct 2021

McMahon DE, Kovarik CL, Damsky W, Rosenbach M, Lipoff JB, Tyagi A, Chamberlin G, Fathy R, Nazarian RM, Desai SR, **Lim HW**, Thiers BH, Hruza GJ, French LE, Blumenthal K, Fox LP, and Freeman

1. Clinical and Pathologic Correlation of Cutaneous COVID-19 Vaccine Reactions including V-REPP: A Registry Based Study. J Am Acad Dermatol 2021.

PMID: 34517079 Epub ahead of print

**Lim HW**, Mohammad TF, and Wang SQ. Food and Drug Administration's proposed sunscreen final administrative order: How does it affect sunscreens in the United States? J Am Acad Dermatol 2021.

PMID: 34606770 Epub: Oct. 2021

**Lim HW**, Kohli I, Ruvolo E, Kolbe L, and Hamzavi IH. Impact of visible light on skin health: The role of antioxidants and free radical quenchers in skin protection. J Am Acad Dermatol 2021; Epub ahead of print.

PMID: 34942294 EPub: Dec. 2021

Rigel D, **Lim HW**, Draelos Z, Weber TM, and Taylor S. Photoprotection For All: Current Gaps and Opportunities.. J Am Acad Dermatol 2021;

PMID: 34942298 Epub. Dec. 2021

Taylor SC, Alexis AF, Armstrong AW, Chiesa Fuxench ZC, and **Lim HW.** Misconceptions of photoprotection in skin of color. J Am Acad Dermatol 2021; Epub ahead of print.

PMID: 34942293 Epub:

Olds H, **Liu J**, **Luk K**, **Lim HW**, **Ozog D**, and **Rambhatla PV**. Telogen effluvium associated with COVID-19 infection. *Dermatol Ther* 2021;

PMID: 33405302 Epub. Jan. 2021

Kashlan R, **Lyons AB**, **Narla S**,and **Hamzavi IH**. Infusion reaction to infliximab biosimilar after transitioning from infliximab. *JAAD Case Rep* 2021; 8:77-79.

PMID: 33532531 Pub: Feb 2021

**Lyons AB**, Zubair R, Kohli I, Nahhas AF, Braunberger TL, Mokhtari M, Ruvolo E, Lim HW, and Hamzavi IH. Mitigating Visible Light and Long Wavelength UVA1-Induced Effects with Topical Antioxidants.

Photochem Photobiol 2021; Epub ahead of print. PMID: 34549819 Pub.

Torres AE**, Lyons AB,**

*Acad Dermatol*. 2021

PMID: 32339702

**Hamzavi IHH, Lim HW**. The role of phototherapy in the era of biologics. *J Am* Feb;84(2):479-485.

Pub: Feb 2021

Torres AE, **Lyons AB, Hamzavi IH, Lim HW.** Response to Commentary on “Role of Phototherapy in the Era of Biologics”. *J Am Acad Dermatol.* 2021 Feb;84(2):e95-e96. PMID: 32950547

Pub: Feb 2021

Torres AE, Awosika O, Maghfour J, Taylor S, and Lim HW. Practical Guide to Tinted Sunscreens. J Am Acad Dermatol 2021; Epub ahead of print.

PMID: 34973975 Pub: Dec. 2021

**Lyons AB, Hamzavi IHH**. Ultraviolet C Induced Skin Reaction for Ultraviolet Germicidal Irradiation of N95 Respirators During the COVID-19 Pandemic. Photoderm Photoimm Photomed. 2021 Mar;37(2):159-160.

PMID: 32974955 Pub: Mar 2021

Adelman M, **Lyons AB, Hamzavi IH**. Comment on “High-dose, high-frequency infliximab: A novel treatment paradigm for hidradenitis suppurativa.” *J Am Acad Dermatol*. 2021 Apr;84(4):e201-e202.

PMID: 33253840 Pub: April 2021

Rehman R, Saad M, Suhrawardy A, and **Kerr H**. Contact Dermatitis and TikTok: A Cross-sectional

Analysis of Trending Content. Dermatitis 2021; Epub ahead of print. PMID: 34967771. Pub. Dec. 2021

**Lyons AB**, **Narla S, Torres AE, Parks-Miller A, Kohli I, Ozog DM, Lim HW, Hamzavi IH**. Skin and Eye Protection Against Ultraviolet C from Ultraviolet Germicidal Irradiation Devices During the COVID-19 Pandemic. *Int J Dermatol*. 2021 Apr;60(4):391-393.

PMID: 33259055 Pub. April 2021

Kohli I, **Lyons AB,** Golding B, Narla S, Torres AE, Parks-Miller A, Ozog D, Lim HW, and Hamzavi IH. UVC Germicidal Units: Determination of Dose Received and Parameters to be Considered for N95 Respirator Decontamination and Reuse. Photochem Photobiol 2020; 96(5):1083-1087.

PMID: 32767758. Pub. April 2021

Horton L, Torres AE, Narla S, **Lyons AB**, Kohli I, Gelfand JM, Ozog DM, Hamzavi IH, and Lim HW. Spectrum of virucidal activity from ultraviolet to infrared radiation. Photochem Photobiol Sci 2020; 19(10):1262-1270.

PMID: 32812619. Pub. April 2021

Kashlan R, **Lyons AB**, Hivnor C, and Ozog DM. N95 Respirators for Dermatologic Surgery and Laser Procedures During COVID-19 and Beyond. Dermatol Surg 2020; 46(11):1441-1442.

PMID: 33105244. Pub: April 2021

**Lyons AB**, Trullas C, Kohli I, Hamzavi IHH, Lim HW. Photoprotection beyond ultraviolet radiation: A review of tinted sunscreens. *J Am Acad Dermatol.* 2021 May;84(5):1393-1397.

PMID: 32335182 Pub. May 2021

**Lyons AB**, Narla S, Kohli I, Zubair R, Nahhas AF, Braunberger TL, Joseph MK, Nicholson CL, Jacobsen G,

and Hamzavi IH. Assessment of Inter-rater Reliability of Clinical Hidradenitis Suppurativa Outcome

Measures Using Ultrasonography. Clin Exp Dermatol 2021

PMID: 34388853 Epub. Aug 2021

Vesper S, Wymer L, Kroner J, Pongracic JA, Zoratti EM, Little FF, Wood RA, Kercsmar CM, Gruchalla RS, Gill MA, Kattan M, Teach SJ, Patel S, Johnson CC, Bacharier LB, Gern JE, **Jackson DJ**, Sigelman SM, Togias A, Liu AH, Busse WW, and Khurana Hershey GK. Association of mold levels in urban children's homes with difficult-to-control asthma. J Allergy Clin Immunol 2021; Epub ahead of print.

PMID: 34606833. Epub: Oct 2021

Osto M, **Hamzavi IH, Lim HW, and Kohli I.** Individual Typology Angle and Fitzpatrick Skin Phototypes are Not Equivalent in Photodermatology. Photochem Photobiol 2021; Epub ahead of print.

PMID: 34796498 Pub: Nov. 2021

Osto M, Edriss M, and **Hamzavi I.** Prospective Protocol Registration Should Be Required for Systematic Reviews in Dermatology Literature. Clin Dermatol 2021; Epub ahead of print.

PMID: 34915149 Pub. Dec 2021

Anderson J, **Maghfour J**, Hamp A, Christensen A, and Dellavalle RP. From the Cochrane Library:

Emollients and Moisturizers for Eczema. Dermatology 2021; 1-3. Epub ahead of print.

PMID: 34511590. Epub:Sept. 2021

**Maghfour J**, Rietcheck H, Szeto MD, Rundle CW, Sivesind TE, Dellavalle RP, Lio P, Dunnick CA, Fernandez J, and Yardley H. Tolerability profile of topical cannabidiol and palmitoylethanolamide: a compilation of single-centre randomized evaluator-blinded clinical and in vitro studies in normal skin. Clin Exp Dermatol 2021; 46(8):1518-1529.

PMID: 34022073. Pub: Dec. 2021

Strock D, **Maghfour J**, and Dellavalle RP. From the Cochrane Library: Interventions for hand eczema. J Am Acad Dermatol 2021; Epub ahead of print.

PMID: 34606772 Pub:

**Maghfour J,** Boothby-Shoemaker W, and Lim HW. Evaluating the United States Population's Interest

in Sunscreen: A Google Trend Analysis. Clin Exp Dermatol 2021; Epub ahead of print.

PMID: 34798683. Epub:Nov. 2021

Vickers C, **Maghfour J, Kohli I, Lim HW, and Hamzavi IH** . Validation of a dermatologic surface area smartphone application: EZBSA. Skin Res Technol 2021; Epub ahead of print.

PMID: 34923672 Pub. Dec. 2021

Jones LR, Levin AM, Dai X, Datta I, Li J, Yin C, and **Mi QS.** MicroRNA Profile Differentiates Head and Neck Keloid and Adjacent Normal Skin Tissue. Facial Plast Surg Aesthet Med 2021;

PMID: 33710934. Epub: Mar 2021

Liu T, Wang J, Subedi K, Yi Q, Zhou L, and **Mi QS**. MicroRNA-155 Regulates MAIT1 and MAIT17 Cell Differentiation. Front Cell Dev Biol 2021; 9:670531.

PMID: 33898469 Pub: April 2021

Jones LR, Levin AM, Dai X, Datta I, Li J, Yin C, and **Mi QS**. MicroRNA Profile Differentiates Head and Neck Keloid and Adjacent Normal Skin Tissue. Facial Plast Surg Aesthet Med 2021; Epub ahead of print.

PMID: 33710934 Epub. Mar 2021

Yang QB, Li LQ, Zhang QB, He YL, **Mi QS,** and Zhou JG. microRNA-223 Deficiency Exacerbates Acute Inflammatory Response to Monosodium Urate Crystals by Targeting NLRP3. J Inflamm Res 2021; 14:1845-1858.

PMID: 34007200 Pub: May 2021

**Mi QS**, Wang J, Liu Q, Wu X, and Zhou L. microRNA dynamic expression regulates invariant NKT cells.

Cell Mol Life Sci 2021; 78(16):6003-6015. PMID: 34236444.

Pub: July 2021

Me R, Gao N, Zhang Y, Lee PSY, Wang J, Liu T, Standiford TJ, **Mi QS**, and Yu FX. IL-36α Enhances Host Defense against Pseudomonas aeruginosa Keratitis in C57BL/6 Mouse Corneas. J Immunol 2021; Epub ahead of print.

PMID: 34686582 Pub. Oct 2021

**Mohammad TF**, and Lim HW. The Important Role of Dermatologists in Public Education on Sunscreens. JAMA Dermatol 2021;

PMID: 33760054. Epub: Mar 2021

**Novice M, Novice T**, Henry NL, Johnson K, Jeruss JS, Kidwell KM, and Burness ML. Identifying Barriers and Facilitators to Scalp Cooling Therapy Through a National Survey of the Awareness, Practice Patterns, and Attitudes of Oncologists. JCO Oncol Pract 2021; Epub ahead of print.

PMID: 34529505 Epub. Sept. 2021

Rehman R, Saad M, Huq F, **Oska S**, Mehregan D, and Daveluy S. A cross-sectional analysis of popular hidradenitis suppurativa content on TikTok. JAAD Int 2021; 5:98-100. PMID: 34693364

**Ozog DM**, Sexton JZ, Narla S, Pretto-Kernahan CD, Mirabelli C, Lim HW, Hamzavi IH, Tibbetts RJ, and Mi QS. The effect of ultraviolet C radiation against different N95 respirators inoculated with SARS-CoV-2. Int J Infect Dis 2020; 100:224-229.

PMID: 32891736. Pub. April 2021

Narla S, Watchmaker J, **Ozog DM**, and Rohrer TE. Cosmetic Practices in the COVID-19 Era. Advances in Cosmetic Surgery 2021; 4(1):109-121.

PMID: Not assigned. Pub: May 2021

Ezekwe N, **Ozog D, and Hamzavi IH**. Response to: "Treatment of hidradenitis suppurativa using a long-

pulsed hair removal neodymium:yttrium-aluminium-garnet laser: A multicenter, prospective, randomized, intraindividual, comparative trial". J Am Acad Dermatol 2021; Epub ahead of print.

PMID: 34293391 Epub: July 2021

Torres AE, **Ozog DM**, and Hruza GJ. Coronavirus Disease 2019 and Dermatology Practice Changes.

Dermatol Clin 2021; 39(4):587-597.

PMID: 34556248

Parashar K, **Torres AE, Boothby-Shoemaker W, Kohli I, Veenstra J,** Neel V, and **Ozog DM**. Imaging Technologies for Pre-surgical Margin Assessment of Basal Cell Carcinoma. J Am Acad Dermatol 2021; Epub ahead of print.

PMID: 34793927

Salameh F, Shumaker PR, Goodman GJ, Spring LK, Seago M, Alam M, Al-Niaimi F, Cassuto D, Chan HH, Dierickx C, Donelan M, Gauglitz GG, Haedersdal M, Krakowski AC, Manuskiatti W, Norbury WB, Ogawa R, Ozog DM, Paasch U, Victor Ross E, Clementoni MT, Waibel J, Bayat A, Goo BL, and Artzi O. Energy-based devices for the treatment of acne scars: 2021 international consensus recommendations. Lasers Surg Med 2021; Epub ahead of print.

PMID: 34719045 Epub: Oct. 2021

Enesu C, Patel A, **Friedman B**. Unique Recognizable Histopathologic Variant of Palisaded Neutrophilic and Granulomatous Dermatitis that is Associate with SRSF2-Mutaed Chronic Myelomonocytic Leukemia: Case Report and Report and Review of the Literature. Am J Dermatopathol.

PMID: 34783709 Epub: Nov. 2021

**Seale, L, Awosika O, Lim H.** Trends in Sessions in Diversity at the American Academy of Dermatology Annual Meetings: 2013-2019. Int J of Women’s Derm. 2021 Jan 28;7(2):197-198.

Davies OMT, Garzon MC, Frieden IJ, Cottrell CE, Gripp KW, Saneto RP, **Shwayder T**, Mirzaa GM, and Drolet BA. Cutaneous vascular anomalies associated with a mosaic variant of AKT3: Genetic analysis continues to refine the diagnosis, nomenclature, and classification of vascular anomalies. J Am Acad

Dermatol 2021. PMID: 34237354 Pub:

Lebwohl MG, **Stein Gold L**, Papp K, Han G, Pariser DM, Lin T, Harris S, and Jacobson A. Long-Term Safety and Efficacy of a Fixed Combination Halobetasol Propionate 0.01%/Tazarotene 0.045% Lotion in Moderate-to-Severe Plaque Psoriasis: Phase 3 Open-Label Study. J Eur Acad Dermatol Venereol 2021.

PMID: 33428282 Epub: Jan 2021

**Stein Gold L**, Paul C, and Romiti R. Efficacy and safety of fixed-dose combination calcipotriol/betamethasone dipropionate foam for the treatment of psoriasis. J Eur Acad Dermatol Venereol 2021; 35 Suppl 1:10-19.

PMID: 33619777 Pub: Feb 2021

Van Voorhees AS, **Stein Gold L,** Lebwohl M, Strober B, Sofen H, Papp K, Bagel J, Zhang Z, Paris M, and Wang Y. Efficacy and safety of a premilast in patients with moderate to severe plaque psoriasis of the scalp: results up to 32 weeks from a randomised, phase 3 study. Br J Dermatol 2021.

PMID: 33763874. Epub: Mar 2021

**Stein Gold L**, and Dirschka T. Why We Should Consider Evidence-Based Treatment Options for Truncal Acne. Dermatol Ther (Heidelb) 2021; Epub ahead of print.

PMID: 33871801. Pub: Apr 2021

Bissonnette R, **Stein Gold L**, Rubenstein DS, Tallman AM, and Armstrong A. Tapinarof in the treatment of psoriasis: A review of the unique mechanism of action of a novel therapeutic aryl hydrocarbon receptor-modulating agent. J Am Acad Dermatol 2021; 84(4):1059-1067.

PMID: 33157177. Pub:

Lebwohl M, Kircik L, Lacour JP, Liljedahl M, Lynde C, Mørch MH, Papp KA, Perrot JL, **Gold LS,** Takhar A, Thaçi D, Warren RB, and Wollenberg A. Twice -weekly topical calcipotriene/betamethasone dipropionate foam as proactive management of plaque psoriasis increases time in remission and is well tolerated over 52 weeks (PSO-LONG trial). J Am Acad Dermatol 2021; 84(5):1269-1277.

PMID: 32950546. Pub:

Baldwin H, Webster G, **Stein Gold L**, Callender V, Cook-Bolden FE, and Guenin E. 50 Years of Topical Retinoids for Acne: Evolution of Treatment. Am J Clin Dermatol 2021; 22(3):315-327.

PMID: 33871811 Pub: May 2021

Blauvelt A, Gordon KB, Lee P, Bagel J, Sofen H, Lockshin B, Soliman AM, Geng Z, Zhan T, Alperovich G, and **Stein Gold L** . Efficacy, safety, usability, and acceptability of risankizumab 150 mg formulation administered by prefilled syringe or by an autoinjector for moderate to severe plaque psoriasis. J Dermatolog Treat 2021;1-9.

PMID: 33947295 EPub: May 2021

Dréno B, and **Stein Gold L**. Acne Scarring: Why We Should Act Sooner Rather Than Later. Dermatol Ther (Heidelb) 2021; Epub ahead of print.

PMID: 34115309 Pub: June 2021

**Gold LS**, Rubenstein DS, Peist K, Jain P, and Tallman AM. Tapinarof cream 1% once daily and benvitimod 1% twice daily are two distinct topical medications. J Am Acad Dermatol 2021; Epub ahead of print.

PMID: 34111499 Pub: June 2021

Harvima RJ, Gooderham M, Tyring S, Thoning H, Nyholm N, and **Stein Gold L**. Clinical, patient and estimated cost benefits of proactive management versus reactive management with calcipotriol/betamethasone dipropionate foam for the treatment of plaque psoriasis in Finland. J Dermatolog Treat 2021; Epub ahead of print.

PMID: 34130573. EPub: June 2021

Lebwohl MG, **Stein Gold L**, Del Rosso JQ, Green L, and Jacobson A. Posttreatment maintenance of therapeutic effect with fixed-combination halobetasol propionate 0.01%/tazarotene 0.045% lotion for moderate-to-severe plaque psoriasis. J Dermatolog Treat 2021; Epub ahead of print.

PMID: 34130581 Epub: June 2021

Lebwohl MG, Tanghetti EA, **Stein Gold L**, Del Rosso JQ, Gilyadov NK, and Jacobson A. FixedCombination Halobetasol Propionate and Tazarotene in the Treatment of Psoriasis: Narrative Review of Mechanisms of Action and Therapeutic Benefits. Dermatol Ther (Heidelb) 2021.

PMID: 34106439 Epub: June 2021

Blauvelt A, Gordon KB, Lee P, Bagel J, Sofen H, Lockshin B, Soliman AM, Geng Z, Zhan T, Alperovich G, and **Stein Gold L.** Efficacy, safety, usability, and acceptability of risan kizumab 150 mg formulation administered by prefilled syringe or by an autoinjector for moderate to severe plaque psoriasis. J Dermatolog Treat 2021.

PMID: 33947295 Epub:

Lebwohl MG, **Stein Gold L**, Papp K, Han G, Pariser DM, Lin T, Harris S, and Jacobson A. Long-term safety and efficacy of a fixed-combination halobetasol propionate 0.01%/tazarotene 0.045% lotion in moderate-to-severe plaque psoriasis: phase 3 open-label study. Journal of the European Academy of Dermatology and Venereology 2021; 35(5):1152-1160.

PMID: Not assigned Pub:

Paller AS, **Stein Gold L**, Soung J, Tallman AM, Rubenstein DS, and Gooderham M. Efficacy and patient-reported outcomes from a phase 2b, randomized clinical trial of tapinarof cream for the treatment of adolescents and adults with atopic dermatitis. J Am Acad Dermatol 2021; 84(3):632-638.

PMID: 32502588 Pub:

**Stein Gold L**, Bhatia N, Tallman AM, and Rubenstein DS. A phase 2b, randomized clinical trial of tapinarof cream for the treatment of plaque psoriasis: Secondary efficacy and patient-reported outcomes. J Am Acad Dermatol 2021; 84(3):624-631.

PMID: 32446832. Pub:

**Stein Gold L**, Del Rosso JQ, Kircik L, Bhatia ND, Hooper D, Nahm W, and Stuart I. Open-label Extension Study Evaluating Long-term Safety and Efficacy of FMX103 1.5% Minocycline Topical Foam for the Treatment of Moderate-to-Severe Papulopustular Rosacea. J Clin Aesthet Dermatol 2020; 13(11):44-49.

PMID: 33282103.

Tanghetti EA, **Stein Gold L**, Del Rosso JQ, Lin T, Angel A, and Pillai R. Optimized formulation for topical application of a fixed combination halobetasol/tazarotene lotion using polymeric emulsion technology. J Dermatolog Treat 2021; 32(4):391- 398.

PMID: 31522563 Pub:

Van Voorhees AS, **Stein Gold L** , Lebwohl M, Strober B, Sofen H, Papp K, Bagel J, Zhang Z, Paris M, and Wang Y. Efficacy and safety of apremilast in patients with moderate to severe plaque psoriasis of the scalp: results up to 32 weeks from a randomised, phase 3 study. The British journal of dermatology 2021.

PMID: Not assigned. Pub:

Bissonnette R, **Gold LS**, Rubenstein DS, Tallman AM, and Armstrong AW. The preponderance of evidence supports an aryl hydrocarbon receptor-dependent mechanism of action of tapinar of. J Am

Acad Dermatol 2021; 85(1):e35-e36. PMID: 33677005 Pub: July 2021

Pinter A, Green LJ, Selmer J, Praestegaard M, **Gold LS**, and Augustin M. A pooled analysis of randomized, controlled, phase 3 trials investigating the efficacy and safety of a novel, fixed dose calcipotriene and betamethasone dipropionate cream for the topical treatment of plaque psoriasis. J Eur Acad Dermatol Venereol 2021; Epub ahead of print. PMID: 34628687

Epub. Oct. 2021

**Stein Gold L**, Baldwin H, Kircik LH, Weiss JS, Pariser DM, Callender V, Lain E, Gold M, Beer K, Draelos Z, Sadick N, Pillai R, Bhatt V, and Tanghetti EA. Efficacy and Safety of a Fixed-Dose Clindamycin Phosphate 1.2%, Benzoyl Peroxide 3.1%, and Adapalene 0.15% Gel for Moderate-to-Severe Acne: A

Randomized Phase II Study of the First Triple-Combination Drug. Am J Clin Dermatol 2021; Epub

ahead of print. PMID: 34674160 Epub: Oct. 2021

Callender VD, Baldwin H, Cook-Bolden FE, Alexis AF, **Stein Gold L** , and Guenin E. Effects of Topical Retinoids on Acne and Post-inflammatory Hyperpigmentation in Patients with Skin of Color: A Clinical Review and Implications for Practice. Am J Clin Dermatol 2021; Epub ahead of print.

PMID: 34751927 Pub:

Grada A, Del Rosso JQ, Graber E, Bunick CG, Stein Gold L, Moore AY, Baldwin H, Obagi Z, Damiani G, Carrothers T, McNamee B, and Hanze E. Sarecycline treatment for acne vulgaris: Rationale for weightbased dosing and limited impact of food intake on clinical efficacy. Dermatol Ther 2021; e15275. Epub ahead of print.

PMID: 34923732 Pub: Dec. 2021

Layton A, Alexis A, Baldwin H, Beissert S, Bettoli V, Del Rosso J, Dréno B**, Gold LS**, Harper J, Lynde C, Thiboutot D, Weiss J, and Tan J. Identifying gaps and providing recommendations to address shortcomings in the investigation of acne sequelae by the Personalising Acne: Consensus of Experts

panel. JAAD Int 2021; 5:41-48. PMID: 34816133 Pub: Dec. 2021

Lebwohl MG, **Stein Gold L**, Strober B, Papp KA, Armstrong AW, Bagel J, Kircik L, Ehst B, Hong HC, Soung J, Fromowitz J, Guenthner S, Piscitelli SC, Rubenstein DS, Brown PM, Tallman AM, and Bissonnette R. Phase 3 Trials of Tapinarof Cream for Plaque Psoriasis. N Engl J Med 2021; 385(24):2219-2229.

PMID: 34879448. Pub: Dec. 2021

Tan J, Alexis A, Baldwin H, Beissert S, Bettoli V, Del Rosso J, Dréno B, Gold LS, Harper J, Lynde C, Thiboutot D, Weiss J, and Layton AM. The Personalised Acne Care Pathway-Recommendations to guide longitudinal management from the Personalising Acne: Consensus of Experts. JAAD Int 2021; 5:101-111.

PMID: 34816135 Pub. Dec. 2021

Tan J, Alexis A, Baldwin H, Beissert S, Bettoli V, Del Rosso J, Dréno B, **Gold LS,** Harper J, Lynde C, Thiboutot D, Weiss J, and Layton AM. Gaps and recommendations for clinical management of truncal acne from the Personalising Acne: Consensus of Experts panel. JAAD Int 2021; 5:33-40.

PMID: 34816132. Pub: Dec. 2021

Pourang, A, **Tisack, A,** Ezekwe, N, Torres, AE, Kohli, I, Hamzavi, IH, Lim, HW. The Effects of Visible Light on Mechanisms of Skin Photoaging. Photodermatol Photoimmunol Photomed.

In press. 2021 Pub:

**Tisack A, Luther C, and Kohen L**. Linear Violaceous Papules in a Child. Cutis 2021; 108(5):241-245.

PMID: Not assigned Pub:

**Tisack A, Singh R, Kohen L**. Rosacea Fulminans Herpeticum: Rosacea Fulminans with Superimposed Herpetic. JAAD Case Reports.

PMID: Pub : Mar 2021

**Tisack A**, Fotouhi A, Fidai C, **Friedman BJ, Ozog D, and Veenstra J**. A Clinical and Biologic Review of Keratoacanthoma. Br J Dermatol 2021; Epub ahead of print.

PMID: 33864244. Pub. April 2021

**Tisack A, Singh RK, and Kohen L**. Rosacea fulminans herpeticum: Rosacea fulminans with superimposed herpetic infection. JAAD Case Reports 2021; 11:106-108.

PMID: 33948471. Pub: May 2021

**Tisack A, Pourang A, Kohli I, Lim HW, and Hamzavi IH**. Recommendations for Reporting Methods in Phototesting Studies. Photochem Photobiol 2021; Epub ahead of print.

PMID: 34312877 Epub: July 2021

**Tisack A**, Fotouhi A, Fidai C, Friedman BJ, Ozog D, and Veenstra J. Response to "A clinical and biological review of keratoacanthoma": reply from authors. Br J Dermatol 2021; Epub ahead of print.

PMID: 34698380 Epub: Oct. 2021

Tisack A, Luther C, and Kohen L. Linear Violaceous Papules in a Child. Cutis 2021; 108(5):241-245. PMID: Not assigned Pub. Dec. 2021

**Vellaichamy G**, Kohli I, Zubair R, Yin C, **Braunberger T**, Nahhas AF, Nicholson C, Mohammad TF, Isedeh P**, Lyons AB**, Nartker N, Al-Jamal M, Matsui M, Karaman-Jurukovska N, Zhou L, Lim HW, Mi QS, and Hamzavi IH. An in vivo model of Postinflammatory Hyperpigmentation and Erythema: Clinical, Colorimetric, and Molecular Characteristics. Br J Dermatol 2021; Epub ahead of print.

PMID: 34625951 Epub: Oct 2021

**Veenstra J,** Buechler CR, Robinson G, Chapman S, Adelman M, **Tisack A**, Dimitrion P, Todter E, Kohen L, and Lim HW. Antecedent immunosuppressive therapy for immune-mediated inflammatory diseases in the setting of a COVID-19 outbreak. J Am Acad Dermatol 2020; 83(6):1696-1703.

PMID: 32735965 Pub: April 2021

**Veenstra J**, Dimitrion P, Yao Y, Zhou L, Ozog D, and Mi QS. Research Techniques Made Simple: Use of Imaging Mass Cytometry for Dermatological Research and Clinical Applications. J Invest Dermatol 2021; 141(4):705-712.e701.

PMID: 33752807 Pub: April 2021

**Veenstra J,** Wang J, McKinnon-Maksimowicz K, Liu T, Zuniga B, Hamzavi I, Zhou L, and Mi QS. Correspondence on 'Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort'. Ann Rheum Dis 2021;

PMID: 34112654. EPub: June 2021

Puiu T, **Veenstra J,** Antonyan AS, Tisack A, Chaffins M. Recurrent Painful Nodules Following Synthol Injection to Enhance Bicep Volume. Cutis. 2021 Feb; 107(2):E24-E26. DOI:1-.12788/ Cutis.0189

PMID: EPub:

Attachment 2 – Publications of department faculty for the last three years.

Bae JM, Zubair R, Ju HJ, Kohli I, Lee HN, Eun SH, Lyons AB, **Vellaichamy G**, Han TY, Lim HW, and Hamzavi IH. Development and Validation of the Fingertip Unit for Assessing Facial Vitiligo Area Scoring Index (F-VASI). J Am Acad Dermatol 2021; Epub ahead of print.

PMID:34246695 Epub: July 2021

**Vellaichamy G**, Townsend SM, **Lyons AB, and Hamzavi IH**. T-cell/histiocyte-rich large B-cell lymphoma in a 27-year-old with hidradenitis suppurativa, psoriasis, and vitiligo: Implications for screening. JAAD Case Rep 2020; 6(12):1252-1253.

PMID: 33294556 Pub: April 2021

**Vellaichamy G**, Dimitrion P, Zhou L, Ozog D, Lim HW, Liao W, Hamzavi IH, and Mi QS. Insights from γ-Secretase: Functional Genetics of Hidradenitis Suppurativa. J Invest Dermatol 2021.

PMID: 33836848 EPub: April 2021

**Vellaichamy G**, **Kohli I,** Zubair R, YinC , **Braunberger,T**, Nahhas,A, Nicholson C, **Mohammad T**, Isedeh P, Lyons, A, Nartker, N, Al-Jamal, M, Matsui, M, Karaman-Jurukovska, N, Li, Z, **Lim, HW,** Mi, **QS,** **Hamzavi, I.** An in vivo model of Postinflammatory Hyperpigmentation and Erythema: Clinical, Colorimetric, and molecular Characteristics. Br J Dermatol.

PMID: In press. 2021

Bi X, **Zhou L**, Liu Y, Gu J, and **Mi Q**. MicroRNA-146a deficiency delays wound healing in normal and diabetic mice. *Adv Wound Care (New Rochelle)* 2021;

PMID: 33554730 Epub. Feb. 2021

Yao Y, Fu C, **Zhou L, Mi QS, and Jiang A** . DC-Derived Exosomes for Cancer Immunotherapy. Cancers (Basel) 2021; 13(15). PMID: 34359569.

PMID: Pub:

**SUBMITTED FOR PUBLICATION**

Eleryan M, **Awosika O,** Manalo I, Yeung H, Kim J. Acknowledging and Addressing the Lack of Underrepresented Minorities in the Mohs Micrographic Surgery and Dermatologic Oncology Workforce: A Call to Action. *JAMA Derm.* Submitted: May 2021.

**Torres AE, Awosika O,** Taylor S, **Lim HW**. A Practical Guide to Tinted Sunscreens. *J Am Acad Dermatol.* Submitted: May 2021.

**2020 Dermatology Publications**

Powell A, Nelson KN, **Awosika O**, Rengifo-Pardo M, and Ehrlich A. Burning Mouth Syndrome and Contact Dermatitis. *Dermatitis* 2020;

PMID: 32091459 Epub: Feb 2020

**Awosika O**. Regarding Subcutaneous Spanginosis of the Breast. J Clin Aesth Derm.

PMID: 31320970 Pub: July 2020

Fatima S, **Braunberger T**, **Mohammad T**, **Kohli I**, and **Hamzavi I**. The role of sunscreen in melasma and postinflammatory hyperpigmentation. *Indian Journal of Dermatology* 2020; 65(1):5-10.

PMID: 32029932 Pub: Jan 2020

*Derm Research*

**Kohli I**, **Braunberger T**, Nahhas A, Lim H, et al. Long-wavelength Ultraviolet A1 and Visible Light Photoprotection: A Multimodality Assessment of Dose and Response.

Photochem Photobiology 96(1):208-214.

PMID:31464341 Pub: Jan 2020 EPub: Sept.2019

*Derm Research*

**Kohli I** , Kastner S, Thomas M, Nahhas AF, **Braunberger TL**, **Mohammad TF**, Nicholson CL, Canfield D, Kollias N, **Lim HW**, **Hamzavi IH**, and Patwardhan SV. Quantitative measurement of skin surface oiliness and shine using differential polarized images. *Arch Dermatol Res* 2020.

PMID: 32270323 Pub: Apr 2020

*Derm Research*

**Braunberger TL**, Adelman M, **Shwayder TA**, Clarke LE, and Friedman BJ. Proliferative nodule resembling angiomatoid Spitz tumor with degenerative atypia arising within a giant congenital nevus. J Cutan Pathol 2020.

PMID: 32776331 Pub: Dec. 2020 Epub: Sept 2020

Vellaichamy G, **Chadha A** , **Hamzavi IH**, and **Lim HW**. Polymorphic Light Eruption Sine Eruptione: A Variant of Polymorphous Light Eruption. *Photodermatol*

*Photoimmunol Photomed* 2020; Epub ahead of print.

PMID: 32323883 Pub: April 2020

Fatima S, D'Sa H, **Chaffins ML**, Menon M, and **Friedman BJ**. An elderly male with a chronic rash on the right foot. *Indian J Dermatol* 2020; 65(3):222-224.

PMID: 32565566 Pub: May 2020

Siegel DR, Schneider SL, **Chaffins M, Rambhatla PV**. A retrospective review of 93 cases of cellular dermatofibromas. *Int J Dermatol*. 2020;59(2):229-235. doi:10.1111/ijd.14472

PMID: 31074502 Pub: May 2020

**Chapman S**, Adelman M, Sullivan A, Mancuso J, Lim HW. Apremilast-associated drug reaction with eosinophilia and systemic symptoms. JAAC Case Report. Mar 25;6(4):302-304

PMID:32258304 Pub: Mar. 2020

Smith J, **Ezekwe N**, **Pourang A**, and **Hamzavi I**. Multifocal Myositis and Elevated CPK associated with the use of Ustekinumab for Hidradenitis Suppurativa. *Br J Dermatol* 2020.

PMID: 33370450 Pub: Dec. 2020

*Derm Research*

**Friedman BJ, Hernandez S, Fidai C, Jiang A, Shwayder**, et al. A pediatric case of pigmented epithelioid melanocytoma with chromosomal copy number alterations in 15q adn17q and a novel NTRK3-SCAPER gene fusion. J Cutan Pathology Jan; 47(1):70-75

PMID: 31437301 Pub. Jan. 2020 Epub. Sept 2019

Umeh ON, Beekman R, Dʼsa H, and **Friedman BJ**. Elderly Man With Progressive Nail Atrophy:

Challenge. *Am J Dermatopathol* 2020; Epub ahead of print.

PMID: 32932300 Epub: Sept. 2020

**Friedman BJ**, **Robinson G**, and **Kohen L**. Dermoscopic Features of Spitz Tumor With LMNA-NTRK1 Fusion. *Dermatol Pract Concept* 2021; 11(1):e2020101.

PMID: 33354405 Pub. Dec. 2020

Narla S, **Kohli I**, **Hamzavi IH**, and **Lim HW**. Visible light in photodermatology. *Photochem Photobiol Sci* 2020; 19(1):99-104.

PMID: 31922171 Pub: Jan. 2020

*Derm Research*

**Hamzavi IH**, **Lyons AB**, **Kohli I**, **Narla S**, **Parks-Miller A** , Gelfand JM, **Lim HW**, and **Ozog D**. Ultraviolet germicidal irradiation: possible method for respirator disinfection to facilitate reuse during COVID-19 pandemic. *J Am Acad Dermatol* 2020.

PMID: 32246972 Epub: April 2020

*Derm Research*

Cohen L, Brodsky MA, Zubair R, Kohli I, **Hamzavi IH** et al. Cutaneous Interaction with Visible Light:

What Do We Know. J Am Acad Dermatol 2020.

PMID: 32289393 Epub: April 2020

*Derm Research*

Worden A, Yoho D, Houin H, Moquin K, **Hamzavi I**, et al. Factors affecting healing in the treatment of Hidradenitis Suppurativa. Ann Plast Surg 2020 Apr; 84(4):436-440

PMID: 31688123 Pub: Apr 2020

Orenstein LAV, Nguyen TV, Damiani G, Sayed C, Jemec GBE, and **Hamzavi I**. Medical and Surgical Management of Hidradenitis Suppurativa: A Review of International Treatment Guidelines and Implementation in General Dermatology Practice. *Dermatology* 2020;

PMID: 32408306 Epub: May 2020

Nguyen TV, Damiani G, Orenstein LAV, **Hamzavi I**, and Jemec G. Hidradenitis Suppurativa: An Update on Epidemiology, Phenotypes, Diagnosis, Pathogenesis, Comorbidities and Quality of Life. *J Eur Acad Dermatol Venereol* 2020;

PMID: 32460374 Epub: May 2020

**Narla S**, Price KN, Sachdeva M, Shah M, Shi V, **Hamzavi I**, Alavi A, and Lowe MA. Proceeding report of the fourth Symposium on Hidradenitis Suppurativa Advances (SHSA) 2019. *J Am Acad Dermatol* 2020; Epub ahead of print.

PMID: 32497690 Pub: June 2020

*Derm Research*

Fransen F, Spuls P, Alam M, Badawi A, Boixeda P, Haedersdal M, **Hamzavi I**, Hedelund L, Kelly KM, Kono T, Laubach HJ, Manuskiatti W, Marini L, Nouri K, Paasch U, Passeron T, Prinsen C, Verner I, and Wolkerstorfer A. Generic outcome set for the international registry on Laser treatments in Dermatology (LEAD): a protocol for a Delphi study to achieve consensus on what to measure. *BMJ Open* 2020; 10(6).

PMID: 32595165 Pub: June 2020

Rosmarin D, Pandya A, Lebwohl M, Grimes P, Hamzavi I, et al. Ruxolitinib cream for treatment of vitiligo: a randomized, controlled, phase 2 trial. 2020 Jul 11;369

PMID: 32653055 Pub: July 2020

Ezzedine K, Vance TM, **Hamzavi IH**, and Qureshi AA. Vitiligo: Targeted Therapies Add Color to Disease., Pathophysiology. *J Invest Dermatol* 2020; 140(8):1498-1500.

PMID: 32709274 Pub: Aug 2020

*Derm Research*

**Narla S**, Azzam M, Townsend S, Vellaichamy G, Marzano AV, Alavi A, Lowes MA, and **Hamzavi IH**. Identifying key components and therapeutic targets of the immune system in hidradenitis suppurativa with an emphasis on neutrophils. Br J Dermatol 2020; Epub ahead of print.

PMID: 32893875 Epub: Sept. 2020 Derm Research

Zouboulis CC, Benhadou F, Byrd AS, Chandran NS, Giamarellos-Bourboulis EJ, Fabbrocini G, Frew JW, Fujita H,González-López MA, Guillem P, Gulliver WPF, **Hamzavi I et al.** What causeshidradenitis suppurativa ? - 15 years after. *Exp Dermatol* 2020;

PMID: 33058306 Epub: Oct 2020

van Geel N, **Hamzavi I** , **Kohli I**, Wolkerstorfer A, **Lim HW**, Bae JM, Lui H, Harris JE, Pandya AG, Thng Tien Guan S, Abdallah M, Esmat S, Seneschal J, Speeckaert R, Grine L, Kang HY, Raboobee N, Xiang LF, Bekkenk M, Picardo M, and Taieb A. Standardizing serial photography for assessing and monitoring vitiligo: A core set of international recommendations for essential clinical and technical specifications. *J Am Acad Dermatol* 2020; 83(6):1639-1646.

PMID: 31678332. Pub. Dec. 2020

*Derm Research*

Oska S, Zarbo A, **Jahnke M**. Sleep-related rhythmic movement disorder: A case report of head banging alopecia. Pediatric Dermatology. Mar 2020; 3792):350-351

PMID: 31930572 Epub: Jan. 2020

Fu C, Peng P, Loschko J, Feng L, Pham P, Cui W, Lee KP, Krug AB, and **Jiang A**. Plasmacytoid dendritic cells cross-prime naive CD8 T cells by transferring antigen to conventional dendritic cells through exosomes. *Proc Natl*

*Acad Sci U S A* 2020; 117(38):23730-23741.

PMID: 32879009 Pub: Sept. 2020

Hoffert M, **Kerr H**, Hegab S, Whitehouse S, Kokas M, MacLean L, Van Harn M, Baker-Genaw K. Designing a Yoga Intervention Program to Improve Well-Being for Physician Trainees: Challenges and Lessons Learned. *Int J Yoga Therap*. 2021

PMID: 33157552 Epub: Nov. 2020

**Kohli I, Lyons AB**, Golding B, **Narla S, Torres AE, Parks-Miller A, Ozog D, Lim HW, and Hamzavi IH.** UVC Germicidal Units: Determination of Dose Received and Parameters to be Considered for N95 Respirator Decontamination and Reuse. Photochem Photobiol 2020.

PMID: 32767758 Epub: Aug. 2020

*Derm Research*

Patel N, **Konda S**, and **Lim HW**. Dupilumab for the Treatment of Chronic Actinic Dermatitis. *Photodermatol Photoimmunol Photomed* 2020;

PMID: 32320500 Pub: April 2020

Wright E, **Kurland E, Lim HW**. Solar urticaria caused by visible light in a 33-year-old male refractory to treatment with omalizumab. Photodermatol Photoimmunol Photomed 2020; 36(4):316-317

PMID: 32141097 Pub: July 2020 Epub: Mar 2020

Buechler CR, **Kurland E, Veenstra J**. Extensive Tinea Associated with Tofacitinib Therapy Masquerading as New-Onset SCLE. SKIN the Journal of Cutaneous Medicine.

PMID: None Pub: Aug 2020

Freeman EE, McMahon DE, Lipoff JB, Rosenbach M, Kovarik C, Desai SR, Harp J, Takeshita J, French LE, **Lim HW**, Thiers BH, Hruza GJ, and Fox LP. The spectrum of COVID-19-associated dermatologicmanifestations: an international registry of 716 patients from 31 countries. *J Am Acad Dermatol* 2020.

PMID: 32622888 Epub: Jan. 2020

Krutmann J, Passeron T, Gilaberte Y, Granger C, Leone G, Narda M, Schalka S, Trullas C, Masson P, and **Lim HW**. Photoprotection of the future: challenges and opportunities. *J Eur Acad Dermatol Venereol* 2020;

PMID: 31898355 Epub: Jan 2020

Menter A, Cordoro KM, **Lim H,** et al: Joint American Academy of Dermatology – National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients. J Am Acad of Dermatol Jan;82(1):161-201

PMID: 31703821 Pub: Jan 2020 Epub: Nov. 2019

Elmets C, Korman N, Prater E, **Lim H**, et al. Joint AAD-NPF Guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures.

PMID: 32738429 Epub. July 2020

**Torres AE**, and **Lim HW**. Photobiomodulation for the management of hair loss. *Photodermatol, Photoimmunol Photomed* 2020.

PMID: 33377535 Epub: Dec. 2020

Levoska MA, Griffith JL, Nagai S, Collins K, and **Lim HW**. A multi-disciplinary approach utilizing filters for surgical procedures in erythropoietic protoporphyria. *J Am Acad Dermatol* 2020;

PMID: 32068036. Epub: Feb 2020

Soliman YS, **Lim HW**, and **Kerr HA**. Recalcitrant, delayed pressure urticaria treated with long-term intravenous immunoglobulin. *JAAD Case Rep* 2020; 6(3):176-177. PMID: 32099887

Epub: Feb 2020

Richard EG, and **Lim HW**. In Memoriam. *Photodermatol Photoimmunol Photomed* 2020; 36(3):171.

PMID: None Pub: March 2020

**Lim HW**, Feldman SR, Van Voorhees AS, and Gelfand JM. Recommendations for phototherapy during the COVID-19 pandemic. *J Am Acad Dermatol* 2020

PMID: 32339700 Epub: April 2020

Freeman EE, McMahon DE, Hruza GJ, Irvine AD, Spuls PI, Smith CH, Mahil SK, Castelo-Soccio L, Cordoro KM,Lara-Corrales I, Naik HB, Alhusayen R, Ingram JR, Feldman SR, Balogh EA, Kappelman MD, Wall D, Meah N,Sinclair R, Beylot-Barry M, Fitzgerald M, French LE, **Lim HW**, Griffiths CEM, and Flohr C. International Collaboration and Rapid Harmonization across Dermatologic COVID-19 Registries. *J Am Acad Dermatol* 2020.

PMID: 32562840 EPub: June 2020

Menter A, Gelfand J, Connor C, **Lim H**, et al. Joint American Academy of Dermatology – National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies. June;82(6):1445-1486

PMID:32119894 Pub: June 20ub: Feb. 2020

Luke J, Cornelius L, and **Lim HW**. Dermatology Resident Selection: Shifting Toward Holistic Review? *J Am Acad Dermatol* 2020

PMID: 33245933 Epub: Nov. 2020

**Luther CA**, Griffith JL, **Kurland E**, Al Shabeeb R, Eleryan M, Redbord K, and **Ozog DM**. The Infection Rate of Intralesional Triamcinolone and The Safety of Compounding in Dermatology for Intradermal and Subcutaneous Injection: A Retrospective Chart Review. *J Am Acad Dermatol* 2020; Epub ahead of

print. PMID: 32442698 Epub: May 2020

**Lyons AB**, Peacock A, McKenzie SA, **Jacobsen G**, Naik HB, Shi VY, **Hamzavi IH**, and Hsiao JL. Evaluation of Hidradenitis Suppurativa Disease Course During Pregnancy and Postpartum. *JAMA Dermatol* 2020.

PMID: 32347884 Epub: Jan 2020

*Derm Research*

**Lyons AB**, Kaddurah H, Peacock A, Zubair R, Vellaichamy G, Norwick P, Ramesh M, Jacobsen G, Hamzavi IH. Hidradenitis suppurativa and risk for development of Clostridium difficile colitis. In J Dermatol 2020

PMID:32010962 Epub: Feb 2020

*Derm Research*

**Lyons AB** , Ghia D, Abdallah M, Abdel-Malek Z, Esmat S, Ezzedine K, Grimes P, Harris JE, Lui H, Manga P, **Mi QS**, Pandya A, Parsad D, Passeron T, Picardo M, Seneschal J, Silpa-Archa N, Taieb A, Xiang F, **Lim** **HW, Hamzavi IH**. Proceeding Report of the Second Vitiligo International Symposium – November 9-10, 2018, Detroit, MI USA

Pigment Cell Melanoma Res. 2020 Jan 27. doi: 10.1111/pcmr.12867.

PMID:31984599 Epub: Mar. 2020/July 2020??

*Derm Research*

Adelman M, **Lyons AB** , **Seale L**, and **Friedman BJ**. Use of p16 immunohistochemical stain to help differentiate inflamed melanocytic nevi from metastatic melanoma in the setting of immunotherapy.

*J Am Acad Dermatol* 2019; PMID: 31765681 Epub: Apr. 2020

*Derm Research*

**Lyons AB**, **Kohli I**, Nahhas AF, **Braunberger TL**, **Mohammad TF**, Nicholson CL, Nartker NT, **Modi K**, Matsui MS, **Lim HW**, and **Hamzavi IH**. Trichloroacetic acid model to accurately capture the efficacy of treatments for postinflammatory hyperpigmentation. *Arch Dermatol Res* 2020.

PMID: 32253506 Epub: April 2020

*Derm Research*

**Lyons AB**, Peacock A, McKenzie SA, Jacobsen G, Naik HB, Shi VY, **Hamzavi IH**, and Hsiao JL.

Retrospective Cohort Study of Pregnancy Outcomes in Hidradenitis Suppurativa. *Br J Dermatol* 2020.

PMID: 32333790 Epub: April 2020

*Derm Research*

**Lyons AB**, Shabeeb N, Nicholson CL, **Braunberger TL**, Peacock A, and **Hamzavi IH**. Emerging medical treatments for hidradenitis suppurativa. *J Am Acad Dermatol* 2020.

PMID: 32289386 Epub: April 2020

*Derm Research*

**Lyons AB**, Trullas C, **Kohli I**, **Hamzavi IH**, and **Lim HW**. Photoprotection Beyond Ultraviolet Radiation:

A Review of Tinted Sunscreens. *J Am Acad Dermatol* 2020.

PMID: 32335182 Epub: April 2020

*Derm Research*

**Torres AE**, **Lyons AB**, **Hamzavi IH**, and **Lim HW**. Role of phototherapy in the era of biologics. *J Am Acad Dermatol* 2020; Epub ahead of print.

PMID: 32339702 Pub: April 2020

*Derm Research*

**Torres AE**, **Lyons AB**, **Narla S**, **Kohli I**, **Parks-Miller A**, **Ozog D**, **Hamzavi IH**, and **Lim HW**. Ultraviolet-C and other methods of decontamination of filtering facepiece N-95 respirators during the COVID-19 pandemic. *Photochem Photobiol Sci* 2020; Epub ahead of print.

PMID: 32412033 Pub: May 2020

*Derm Research*

**Narla S**, Oska S, **Lyons AB**, **Lim HW**, and **Hamzavi IH**. Association of myalgias with compounded topical Janus kinase inhibitor use in vitiligo. *JAAD Case Rep* 2020; 6(7):637-639.

PMID: 32613059 Pub: May 2020

*Derm Research*

**Lyons A**, Abbas Z, **Mohammad TF, Hamzavi I** . Use of autologous, non-cultured melanocyte-keratinocyte transplantation in patients with stable genital leukoderma. Derm Surg

PMID: 31343442 Pub. Sept. 2020

*Derm Research*

**Lyons AB**, and **Hamzavi IH**. Ultraviolet C Induced Skin Reaction from Ultraviolet Germicidal Irradiation of N95Respirators During the COVID-19 Pandemic. *Photodermatol Photoimmunol Photomed* 2020; Epub ahead of print.

PMID: 32974955 Epub: Sept. 2020

*Derm Research*

Kashlan R, **Lyons AB**, Hivnor C, and **Ozog DM**. N95 Respirators for Dermatologic Surgery and Laser Procedures During COVID-19 and Beyond. *Dermatol Surg* 2020; 46(11):1441-1442.

PMID: 33105244 Pub: Nov. 2020

*Derm Research*

**Lyons AB**, **Narla S**, **Torres AE**, **Parks -Miller A**, **Kohli I** , **Ozog DM**, **Lim HW**, and **Hamzavi IH**. Skin and eye protection against ultraviolet C from ultraviolet germicidal irradiation devices during the COVID-19 pandemic. *Int J Dermatol* 2020.

PMID: 33259055 Pub: Dec. 2020

*Derm Research*

Price KN, **Lyons AB**, **Hamzavi IH**, Hsiao JL, and Shi VY. Facilitating Clinical Trials Participation of Low Socioeconomic Status Patients. *Dermatology* 2020:1-4.

PMID: 33321504 EPub: Dec. 2020

*Derm Research*

**Vellaichamy G**, Townsend SM, **Lyons AB, and Hamzavi IH**. T-cell/histiocyte-rich large B-cell lymphoma in a 27-year-old with hidradenitis suppurativa, psoriasis, and vitiligo: Implications for screening. *JAAD Case Reports* 2020; 6(12):1252-1253

PMID: 33294556 Pub: Dec. 2020

*Derm Research*

Zalfa A Abdel-Malek, Jordan C, Ho T, Upadhyay P, Fleischer A, **Hamzavi I.** The enigma and challeges of vitiligo pathophysiology and treatment. Pigment Cell Melanoma Res. 2020 Nov; 33(6)778-787.

PMID:32198977 Pub. Nov. 2020

Teran VA, **McHargue CA**, and Gru AA. Photodistributed Rash Progressing to Erythroderma: Answer.

*Am JDermatopathol* 2020; 42(6):463-465.

PMID: 32433320 Pub: June 2020

Madan E, Peixoto ML, Dimitrion P, Eubank TD, Yekelchyk M, Talukdar S, Fisher PB, **Mi QS**, Moreno E,and Gogna R. Cell Competition Boosts Clonal Evolution and Hypoxic Selection in Cancer. *Trends Cell Biol* 2020; 30(12):967-978.

PMID: 33160818 Pub. Nov. 2020 Derm Research

Hamel R, **Mohammad TF**, Chahine A, Joselow A, Garrett V, Radosta S, Boh E, Alora-Palli M, Mistur RL, Baron ED, Cooper KD, and **Lim HW**. Comparison of racial distribution of photodermatoses in USA academic dermatology clinics: a multicenter retrospective analysis of 1080 patients over a 10-year period. *Photodermatol Photoimmunol Photomed* 2020.

PMID: 32104953 Epub: Feb. 2020

Yao Y, Liu Q, Adrianto I, Wu X, Glassbrook J, Khalasawi N, Yin C, Yi Q, Dong Z, Geissmann F, **Zhou L**, and **Mi QS**. Histone deacetylase 3 controls lung alveolar macrophage development and homeostasis. *Nat Commun* 2020;

11(1):3822.

PMID: 32732898 Pub: July 2020

*Derm Research*

Xu Y, Dimitrion P, Cvetkovski S, Zhou L, and **Mi QS.** Epidermal resident γδ T cell development and

function in skin. Cell Mol Life Sci 2020; Epub ahead of print. PMID: 32803399. Pub:

Aug. 2020

*Derm Research*

Ma Z, Li L, Livingston MJ, Zhang D, **Mi Q**, Zhang M, Ding HF, Huo Y, Mei C, and Dong Z. p53/microRNA-214/ULK1 axis impairs renal tubular autophagy in diabetic kidney disease. J Clin Invest 2020; Epub ahead of print.

PMID: 32804155 Epub: Sept. 2020

*Derm Research*

Li D, Peng H, Qu L, Sommar P, Wang A, Chu T, Li X, Bi X, Liu Q, Sérézal IG,

Rollman O, Lohcharoenkal W, Zheng X, Angelstig SE, Grünler J, Pivarcsi A,

Sonkoly E, Catrina SB, Xiao C, Ståhle M, **Mi QS**, Zhou L, Landén NX. miR-19a/b and miR-20a promote wound healing by regulating the inflammatory response of

keratinocytes. J Invest Dermatol. 2020 Sep 16.

PMID: 32949564 Pub. Sept 2020

*Derm Research*

**Narla S**, and Silverberg JI. Multimorbidity and mortality risk in hospitalized adults with chronic inflammatory skin disease in the United States. *Arch Dermatol Res* 2020; Epub ahead of print.

PMID: 32047999 Epub: Feb 2020

*Derm Research*

**Narla S**, **Lyons AB**, **Kohli I**, **Torres AE**, **Parks-Miller A**, **Ozog DM**, **Hamzavi IH**, and **Lim HW**. The Importance of the Minimum Dosage Necessary for UVC Decontamination of N95 Respirators during the COVID-19 Pandemic. *Photodermatol Photoimmunol Photomed* 2020; Epub ahead of print.

PMID: 32291807 Epub: April 2020

*Derm Research*

**Narla S**, and Silverberg JI. The inpatient burden and comorbidities of pyoderma gangrenosum in adults in the United States. *Arch Dermatol Res* 2020.

PMID: 32620994 Epub: July 2020

*Derm Research*

**Ozog D**, **Parks-Miller A**, **Kohli I**, **Lyons AB**, **Narla S**, **Torres AE**, **Levesque M**, **Lim HW**, and **Hamzavi IH**. The Importance of Fit-Testing in Decontamination of N95 Respirators: A Cautionary Note. *J Am Acad Dermatol* 2020.

PMID: 32389714 Epub: May 2020

*Derm Research*

**Torres A, Ozog D, Hamzavi I, Lim H.** Comment on: Proposed approach for reusing surgical masks in COVID-19 pandemic. JAAD 2020 Sep;83(3)

PMID: 32446829 Pub: Sept. 2020 Epub. May 2020

*Derm Research*

**Ozog DM**. Commentary on Treatment of Hypertrophic Burn and Traumatic Scars With 2940 mm Fractional Ablative: YAG. *Dermatol Surg* 2020; 46(6):794-795

PMID: 32452977 Pub: June 2020

Ellis MM, Jones LR, Siddiqui F, Sunkara PR, and **Ozog DM**. The Efficacy of Surgical Excision Plus Adjuvant Multimodal Therapies in the Treatment of Keloids: A Systematic Review and Meta-Analysis. *Dermatol Surg* 2020.

PMID: 32224709 Epub: Aug. 2020

**Ozog DM**, Sexton JZ, **Narla S**, Pretto-Kernahan CD, Mirabelli C, **Lim HW**, **Hamzavi IH**, **Tibbetts RJ**, and **Mi QS**. The Effect of Ultraviolet C Radiation Against Different N95 Respirators Inoculated with SARS-CoV-2. *Int J Infect Dis* 2020; Epub ahead of print.

PMID: 32891736 Epub: Sept. 2020

Alam M, Harikumar V, Ibrahim SA, Kang BY**, Ozog DM**, et al. Principles for developing and adapting clinical practice guidelines and guidance for pandemics, wars, shortages, and other crises and emergencies: the PAGEcriteria. *Arch Dermatol Res* 2020; Epub ahead of print.

PMID: 33206210 EPub: Nov 2020

Alam M, Harikumar V, Kang BY, Ibrahim SA, Kibbi N, Owen JL, Maher IA, Cartee TV, Sobanko JF, Reynolds KA, Bolotin D, Waldman AH, Minkis K, Petersen B, Council ML, Nehal KS, Xu YG, Jiang SB, Somani AK, Bichakjian CK, Huang CC, Eisen DB, **Ozog D et al.** Development of international clinical practice guidelines: benefits, limitations, and alternative forms of international collaboration. *Arch Dermatol Res* 2020.

PMID: 33216212. EPub: Nov. 2020

Harikumar V, Worley B, Ibrahim SA, Kang BY, Maher IA, Cartee TV, Sobanko JF, **Ozog DM**, et. al. Broad versus narrow clinical practice guidelines: avoiding rules for the high risk 1. *Arch DermatolRes* 2020;

PMID: 33175206 EPub: Nov. 2020

**Robinson G**, Townsend S, and **Jahnke MN** . Molluscum Contagiosum: Review and Update on Clinical Presentation, Diagnosis, Risk, Prevention, and Treatment. *Current Dermatology Reports* 2020; 9(1):83-92.

PMID: None Pub: Feb. 2020

Robinson G, McMichael A, Wang S, **Lim H**. Sunscreen and frontal fibrosing alopecia: A Review. JAAD Mar;82(3)723-728.

PMID: 31654665 Pub: Mar 2020 Epub: Oct 2019

Abou Shaar R, Zia S, Alhamar M, **Romano T**, Shaw B, Keller C, and **Friedman BJ**. Salivary gland hyalinizing clear cell carcinoma with cutaneous metastasis: a rare and deceptive tumor. *J Cutan Pathol* 2020; e0e0 July 8.

PMID: 32640078 Epub: July 2020

Vickers C, Oberlin D, and **Shwayder T**. A girl with loose anagen hair syndrome and concurrent uncombable hair syndrome. *JAAD Case Reports* 2020; 6(2):92-95. PMID: 32051838

Pub: Jan 2020

**Gold LS**, Del Rosso JQ, Kircik L, Bhatia ND, Hooper D, Nahm WK, and Stuart I. Minocycline 1.5% foam for the topical treatment of moderate to severe papulopustular rosacea: Results of 2 phase 3, randomized, clinical trials. *J Am Acad Dermatol* 2020.

PMID: 32004648 Epub: Jan 2020

Cartwright MM, Graber EM, **Stein Gold L.**J Drugs Dermatol. 2020 Jan 1;19(1):12-18.J Drugs Dermatol. **2020**;19(1):12-18.

PMID:31985193 Pub: Jan. 2020

**Stein Gold L**, Bagel J, Allenby K, Sidgiddi S. Betamethasone dipropionate spray 0.05% alleviates troublesome symptoms of plaque psoriasis Cutis. 2020 Feb;105(2):97-102;E1.

PMID: 32186532 Pub: Feb. 2020

Thiboutot D, Anderson R, Cook-Bolden F, Draelos Z, Gallo R, Granstein R, Kang S, Macsai M, **Gold LS**, and Tan J. Standard Management Options for Rosacea: the 2019 Update by the National Rosacea Society Expert Committee. *J Am Acad Dermatol* 2020.

PMID: 32035944. Epub: Feb 2020

Van Voorhees AS, **Stein Gold L**, Lebwohl M, Strober B, Lynde C, Tyring S, Cauthen A, Sofen H, Zhang Z, Paris M,and Wang Y. Efficacy and safety of apremilast in patients with moderate to severe plaque psoriasis of the scalp: Results of a phase 3b, multicenter, randomized, placebo-controlled, double-blind study. *J Am Acad Dermatol* 2020;83(1):96-103.

PMID: 32032692 Pub: July 2020

[Del Rosso JQ, Kircik LH, **Stein Gold L,** Thiboutot D.J Androgens, Androgen Receptors, and the Skin:](https://pubmed.ncbi.nlm.nih.gov/32550699/) [From the Laboratory to the Clinic With Emphasis on Clinical and Therapeutic Implications.](https://pubmed.ncbi.nlm.nih.gov/32550699/) Drugs Dermatol. 2020 Mar 1;19(3):30- 35.

J Drugs Dermatol. **2020**;19(3 Suppl 1):s30-35.

PMID: 32550699 Pub: Mar 2020

Eichenfield L, Hebert A, **Gold LS**, Cartwright M, Fragasso E, Moro L, and Mazzetti A. Open-label, long-term extension study to evaluate the safety of clascoterone (CB-03-01) cream, 1% twice daily, in patients with acne vulgaris. *J Am Acad Dermatol* 2020; 83(2):477-485.

PMID: 32348828 Pub: April 2020

Hebert A, Thiboutot D, **Stein Gold L**, Cartwright M, Gerloni M, Fragasso E, and Mazzetti A. Efficacy and Safety of Topical Clascoterone Cream, 1%, for Treatment in Patients With Facial Acne: Two Phase 3 Randomized Clinical Trials. *JAMA Dermatol* 2020; Epub ahead of print.

PMID: 32320027 Pub: April 2020

**Gold LS**, Hansen JB, Patel D, Veverka KA, and Strober B. PGAxBSA composite versus PASI: Comparison across disease severities and as therapeutic response measure for Cal/BD foam in plaque psoriasis. *J Am Acad Dermatol* 2020; Epub ahead of print.

PMID: 32430142 Pub: May 2020

**Gold LS**, Bhatia N, Tallman AM, and Rubenstein DS. A Phase IIb, Randomized Clinical Trial of Tapinarof Cream for the Treatment of Plaque Psoriasis: Secondary Efficacy and Patient-Reported Outcomes. *J Am Acad Dermatol* 2020; Epub ahead of print.

PMID: 32446832 Pub: May 2020

[**Stein Gold L**, Elewski B, Draelos Z, Jacobson A, Lin T.J. Halobetasol 0.01%/Tazarotene 0.045% Lotion](https://pubmed.ncbi.nlm.nih.gov/32484629/) [for Moderate-to-Severe Psoriasis: Pooled Phase 3 Analysis of Males and Females.](https://pubmed.ncbi.nlm.nih.gov/32484629/) Drugs Dermatol. 2020 May 1;19(5):504-514.

PMID: 32484629 Pub. May 2020

Paller AS, **Gold LS**, Soung J, Tallman AM, Rubenstein DS, and Gooderham M. Efficacy and Patient-Reported Outcomes from a Phase IIb, Randomized Clinical Trial of Tapinarof Cream for the Treatment of Adolescents and Adults with Atopic Dermatitis. *J Am Acad Dermatol* 2020.

PMID: 32502588 Epub: June 2020

[**Stein Gold LF**, Takiya L, Zang C, Sanders P, Feldman SR.J. Demographics and Baseline Disease](https://pubmed.ncbi.nlm.nih.gov/32574023/) [Characteristics of Early Responders to Crisaborole for Atopic Dermatitis.](https://pubmed.ncbi.nlm.nih.gov/32574023/) Drugs Dermatol. 2020 Jun 1;19(6):619-624.

PMID: 32574023 EPub: June 2020

Danby SG, Draelos ZD, **Gold LF**, Cha A, Vlahos B, Aikman L, Sanders P, Wu-Linhares D, and Cork MJ.

Vehicles for atopic dermatitis therapies: more than just a placebo. *J Dermatolog Treat* 2020.

PMID:32654550 Epub: July 2020

Lebwohl MG, Papp KA, **Stein Gold L**, Gooderham MJ, Kircik LH, Draelos ZD, Kempers SE, Zirwas M, Smith K, Osborne DW, Trotman ML, Navale L, Merritt C, Berk DR, and Welgus H. Trial of Roflumilast Cream for Chronic Plaque Psoriasis. *N Engl J Med* 2020; 383(3):229-239.

PMID: 32668113 Pub: July 2020

**Stein Gold L**, Alonso-Llamazares J, Lacour JP, Warren RB, Tyring SK, Kircik L, Yamauchi P, and Lebwohl M. PSOLONG:Design of a Novel, 12-Month Clinical Trial of Topical, Proactive Maintenance with Twice-Weekly Cal/BD Foam

in Psoriasis. *Adv Ther* 2020;

PMID: 32965655 Epub: Sept. 2020

Lebwohl M, Kircik L, Lacour JP, Liljedahl M, Lynde C, Mørch MH, Papp KA, Perrot JL, **Gold LS**, Takhar A, Thaçi D, Warren RB, and Wollenberg A. Twice -weekly topical calcipotriene / betamethasone dipropionate foam as proactive management of plaque psoriasis increases time in remission and is well tolerated over 52 weeks (PSO-LONG trial). *JAm Acad Dermatol* 2020; Epub ahead of print.

PMID: 32950546 EPub: Sept. 2020

Bissonnette R, **Gold LS**, Rubenstein DS, Tallman AM, and Armstrong A. Tapinarof in the treatment of psoriasis: A review of the unique mechanism of action of a novel therapeutic AhR modulating agent(TAMA). *J Am Acad Dermatol* 202.

PMID: 33157177

EPub: Nov. 2020

**Stein Gold L,** Del Rosso JQ, Kircik L, Bhatia ND, Hooper D, Nahm W, Stuart I.J Clin Aesthet Dermatol. 2020 Nov;13(11):44-49. Epub 2020 Nov 1. PMID: 33282103 Pub. Nov. 2020

**Tisack Boucher A**, **Jiang A**, and **Veenstra J**. Crusted, ulcerated plaques on the scalp and face. *Clin Exp Dermatol* 2020;

PMID: 32959399 Epub: Sept. 2020

Horton L, **Torres AE,** Narla S, **Lyons AB**, Kohli I, Gelfand JM, **Ozog DM**, **Hamzavi IH, and Lim HW**.

Spectrum of virucidal activity from ultraviolet to infrared radiation. Photochem Photobiol Sci 2020.

PMID: 32812619 Epub: Aug 2020

*Derm Research*

**Torres AE**, **Lyons AB**, **Hamzavi IH**, and **Lim HW**. Response to Commentary on "Role of Phototherapy in the Era of Biologics". *J Am Acad Dermatol* 2020; Epub ahead of print. PMID: 32950547

Epub: Sept. 2020

Novice K, Veenstra J, Siegel D, Kerr H. Dupilumab-Induced Psoriasiform Dermatitis. SKIN. Jan 2020

PMID: None Pub. Jan 2020

Schuler A, **Veenstra J**, **Tisack Boucher A**. Folliculitis Induced by Laser Hair Removal: Proposed Mechanism and Treatment. J Clin Aesthet Dermatol 2020 May;13(5):34-36.

PMID: 32802254 Epub: May 2020 Case Report/Abstract

Adelman M, **Veenstra J**, Wollner I, McGoey J. Why is My Skin Turning Black? A Rare Side Effect of Capecitabine. SKIN May 2020

PMID: None Pub. May 2020

**Veenstra J**, Buechler CR, **Robinson G**, **Chapman S**, Adelman M, **Tisack A,** Dimitrion P, Todter E, **Kohen L**, and **Lim HW**. Antecedent Immunosuppressive Therapy for Immune-Mediated Inflammatory Diseases in the Setting of a COVID-19 Outbreak. *J Am Acad Dermatol* 2020.

PMID: 32735965 Epub: July 2020

Buechler CR, **Veenstra J, and Gold LS**. Topical Therapies for Psoriasis in Phase 3 Trials. Current Dermatology Reports 2020; 9(4):331-338

|  |  |
| --- | --- |
| PMID: None | Dec. 2020 |

**Yeager DG, Ozog DM**. et al. Update and Review of Bleeding Considerations in Dermatologic Surgery.

Hemostatic Techniques and Treatment Strategies for Bleeding Complications. Derm Surg.

PMID: 31592926 Epub. Feb. 2020

Iyengar S, **Yeager DG**, Cohen JL, and **Ozog DM**. Update and Review of Bleeding Considerations in Dermatologic Surgery: Anticoagulants and Antiplatelets. *Dermatol Surg* 2020; 46(2):192-201.

PMID: 31743247 Epub. Feb 2020

Oska S, **Zarbo A**, and **Jahnke MN**. Sleep-related rhythmic movement disorder: A case report of head

banging alopecia. *Pediatr Dermatol* 2020; Epub ahead of print. PMID: 31930572

Epub: Jan 2020

Oska S, **Zarbo A**, **Yeager D**, **Friedman BJ**, and **Shwayder T**. Melanoma arising in a patient with ataxia-telangiectasia: A call for full skin examinations in this patient population. *Pediatr Dermatol* 2020.

PMID: 32413934. Pub: July 2020 Epub: May 2020

**Zarbo A**, **Inamdar K**, and **Friedman BJ**. Tender Nodules on the Extremities: Answer. *Am J Dermatopathol* 2020; 42(11):889.

PMID: 33086227 Pub. Nov. 2020

Huang L, Li GH, Yu Q, Xu Y, Cvetkovski S, Wang X, Parajuli N, Udo-Inyang **I**, Kaplan D, **Zhou L**, Yao Z, and **Mi QS**. Smad2/4 Signaling Pathway Is Critical for Epidermal Langerhans Cell Repopulation Under Inflammatory Condition but Not Required for Their Homeostasis at Steady State. *Front Immunol* 2020;

11:912. PMID: 32457763 Pub: May 2020

**Zhou L**, Adrianto I, Wang J, Wu X, Datta I, and **Mi QS**. Single-Cell RNA-Seq Analysis Uncovers Distinct Functional Human NKT Cell Sub-Populations in Peripheral Blood. *Frontiers in Cell and Developmental Biology* 2020; 8.

PMID: 32528956 Pub: June 2020

*Derm Research*

Yu Q, Parajuli N, Yi Q, Mishina Y, Elder JT, **Zhou L**, and **Mi QS**. ALK3 is not required for the embryonic development, homeostasis and repopulation of epidermal Langerhans cells in steady and inflammatory states. *J Invest Dermatol* 2020.

PMID: 33359325 Pub: Dec 2020

Fu C, **Zhou L**, **Mi QS**, and **Jiang A**. Dc-based vaccines for cancer immunotherapy. *Vaccines* 2020;8(4):1-16.

PMID: 33255895 Pub. Dec. 2020

Zarbo A, Luk KM, Shwayder TA, Friedman BJ. Congenital midline nodules on the chin and sternum. Pediatric Dermatol. 2020 Nov;37(6):1145-1146

PMID: 33283934 Pub: Nov. 2020

Ellis, M, O’Donnell, DR, Young, R, Abouljoud, M, **Lim, HW**. The Physician Leadership Institute bridges the gap in physician-leader development. Physician Leadership Journal. Physician Leadership Journal. July/August 2020; p. 47-52.

**2019 Dermatology Publications**

1. Qureshi AA, **Awosika O**, Nelson K, Brodsky S, Wang H, and Ehrlich A. Retrospective Review of Insurance Coverage for Patch Testing *Ann Allergy Asthma Immunol* 2019; Epub ahead of print

PMID: 30802503 Epub ahead of print: Feb. 2019

1. Qureshi AA, **Awosika O**, Baruffi F, Rengifo-Pardo M, and Ehrlich A. Psychological Therapies in Management of Psoriatic Skin Disease: A Systematic Review *Am J Clin Dermatol* 2019;

PMID: 30937679 Pub: Oct. 2019

1. Wiwanitkit V, Kazemi A, **Awosika O**, and Burgess C. Regarding Subcutaneous Sparganosis of the Breast. *J Clin Aesthet Dermatol* 2019; 12(5):13.

PMID: 31320970 EPub ahead of print: May 2019

1. Kazemi A, **Awosika O**, and Burgess C. Author response. *J Clin Aesthet Dermatol* 2019; 12(5):13-14.

PMID:Not Assigned Pub:Aug. 2019

1. Marchitto MC, **Awosika O**, et al. Emerging Nonsteroid-Based Procedural Therapies for Alopecia Areata: A Systematic Review. *Dermatol Surg* 2019.

PMID: 31403534 Pub: Dec 2019

1. Nahhas AF, **Braunberger TL**, and **Hamzavi IH**. An Update on Drug-Induced Pigmentation *Am J Clin Dermatol* 2019; 20(1):75-96.

PMID: 30374894 Pub: Feb. 2019

1. **Kohli I**, Nahhas AF, **Braunberger TL**, Chaowattanapanit S, **Mohammad TF**, Nicholson CL, Kollias N, **Lim HW**, and **Hamzavi IH**. Spectral Characteristics of Visible Light-induced Pigmentation, and Visible Light Protection Factor. *Photodermatol Photoimmunol Photomed* 2019;

PMID: 31152612 Epub ahead of print June 2019

1. Nahhas AF, **Braunberger TL**, and **Hamzavi IH**. Update on the Management of Vitiligo *Skin Therapy Lett* 2019; 24(3):1-6.

PMID: 31095346 Pub:May 2019

1. Kohli I, **Braunberger TL**, Nahhas AF, Lyons AB, Lim HW, Hamzavi IH. Long Wavelength Ultraviolet A1 and Visible Light Photoprotection: A Multimodality Assessment of Dose and Response. *Photochem Photobiol* 2019;

PMID: PMID: 31464341 Epub ahead of print Sept. 2019

10. **Chadha A**, and **Jahnke M**. Common Neonatal Rashes. *Pediatr Ann* 2019; 48(1):e16-e22.

PMID: 30653638 Pub: Jan 2019

1. **Farmer C**, Patel D, Pimental JD, **Shwayder T**. Large hemorrhagic plaque with central crusting. Cutis. Feb 2019 103(2)68;79;80

PMID:30893389 Epub ahead of print: Feb 2019

1. Artz CE, **Farmer CM and Lim HW**. Polymorphous Light Eruption: A Review. Current Dermatol Report 2019; 8(3)110-116.

PMID: Not Assigned Pub: Aug 2019

1. **Friedman BJ**, Hernandez S, Fidai C, Jiang A, **Shwayder TA**, et al. A Pediatric Case of Pigmented Epithelioid Melanocytoma with Chromosomal Copy Number Alterations in 15q and 17q and a Novel ntrk3-Scaper Gene Fusion. *J Cutan Pathol* 2019;

PMID: 31437301 Epub ahead of print: Sept 2019

1. **Friedman BJ**, and Lee JB. Spitz nevi in older adults: correlation of histopathology with results of a gene expression profiling assay. J Am Acad Dermatol 2019.

PMID: 31866264 Epub ahead of print: Dec 2019

1. Adelman M, Lyons AB, Seale, **Friedman BJ**. Use of p16 immunohistochemical stain to help differentiate inflamed melanocytic nevi from metastatic melanoma in the setting of immunotherapy. J Am Acad Derm. 2019

PMID: 31756681 Epub ahead of print: Nov. 2019

1. Shavit E, Alavi A, Bechara FG, Bennett RG, Bourcier M, Cibotti R, Daveluy S, Frew JW, Garg A, **Hamzavi I**, Hoffman LK, Hsaio J, Kirby JS, Lev-Tov H, Martinez E, Micheletti R, Naik HB, NassifA, Nicholson C, **Parks-Miller A**, Patel Z, Piguet V, **Ramesh M**, Resnik B, Sayed C, Schultz G, **Siddiqui A**, Tan J, Wortsman X, and Lowes MA. Proceeding report of the Second Symposiumon Hidradenitis Suppurativa Advances (SHSA) 2017 *Exp Dermatol* 2019; 28(1):94-103.

PMID: 30484907 Pub: Jan 2019

1. Alikhan A, Sayed C, Alavi A, Alhusayen R, Brasasard A, Burkhart C, Crowell K, Eisen D, Gottlieb A, **Hamzavi I**, Hazen P, Jaleel T, Kimball A, Kirby J, Lowes MA, Micheletti R, **Miller A**, Naik HB, Orgill D, and Poulin Y. North American Clinical Management Guidelines for Hidradenitis Suppurativa: a Publication from the United States and
2. Canadian Hidradenitis Suppurativa Foundations. Part I: Diagnosis, Evaluation, and the use of Complementary and Procedural Management. *J Am Acad Dermatol* 2019;

PMID: 30872156 Epub ahead of print: March 2019

1. Alikhan A, Sayed C, Alavi A, Alhusayen R, Brasasard A, Burkhart C, Crowell K, Eisen D, Gottlieb A, **Hamzavi I**, Hazen P, Jaleel T, Kimball A, Kirby J, Lowes MA, Micheletti R, **Miller A**, Naik HB, Orgill D, and Poulin Y. North American Clinical Management Guidelines for Hidradenitis Suppurativa: a Publication from the United States and Canadian Hidradenitis Suppurativa Foundations. Part II: Topical, Intralesional, and Systemic medical Management. *J Am Acad Dermatol* 2019;

PMID: 30872149 Epub ahead of print-March 2019

1. Eleftheriadou V, **Hamzavi I**, Pandya AG, Grimes P, Harris JE, **Huggins RH**, **Lim HW**, Elbuluk N, **Bhatia B**, Tovar-Garza A, **Nahhas AF**, **Braunberger T**, and Ezzedine K. International Initiativefor Outcomes (INFO) for vitiligo: workshops with patients with vitiligo on repigmentation. *Br J Dermatol* 2019; 180(3):574-579.

PMID: 30030843 Pub: Mar 2018

1. Posso-De Los Rios CJ, Sarfo A, Ghias M, Alhusayen R, **Hamzavi I**, Lowes MA, and Alavi A. Proceeding report of the Third Symposium on Hidradenitis Suppurativa Advances (SHSA) 2018. *Exp Dermatol* 2019; Epub ahead of print

PMID: 30924968 Epub ahead of print: Apr 2019

1. van Geel N, Wolkerstorfer A, Ezzedine K, Pandya AG, Bekkenk M, Grine L, Van Belle S, Lommerts JE, **Hamzavi I**, Harris JE, Eleftheriadou V, Esmat S, Kang HY, Kumarasinghe P, Lan CE, Parsad D, Raboobee N, Xiang LF, Suzuki T, Prinsen CA, Taieb A, Picardo M, and Speeckaert R. Validation of a Physicians Global Assessment (PGA) tool for vitiligo extent: results of an international vitiligo expert meeting *Pigment Cell Melanoma Res* 2019.

PMID: 30945409 Epub ahead of print May 2019

1. **Kohli I**, **Lim HW**, and **Hamzavi IH**. Caution Regarding Testing for Long Wavelength Ultraviolet A1 and Visible Light Effects on Human Skin In Vivo *Photodermatol Photoimmunol Photomed* 2019.

PMID: 31136013 Epub ahead of print June 2019

1. **Kohli I**, Sakamaki T, Tian WD, Moyal D, **Hamzavi IH**, and Kollias N. The dynamics of pigment reactions of human skin to ultraviolet-A radiation. *Photodermatol Photoimmunol Photomed* 2019.

PMID: 31206816 Epub ahead of print July 2019

1. **Kohli I**, **Zubair R**, **Lyons AB**, Nahhas AF, **Braunberger TL**, Mokhtari M, Ruvolo E, **Lim HW**, and **Hamzavi IH**. Impact of Long Wavelength Ultraviolet A1 and Visible Light on Light-Skinned Individuals. *Photochem Photobiol* 2019; Epub ahead of print

PMID: 31344760 Epub ahead of print: Aug 2019

1. Garg A, Neuren E, Cha D, Kirby JS, Ingram JR, Jemec GBE, Esmann S, Thorlacius L, Villumsen B, Marmol VD, Nassif A, Delage M, Tzellos T, Moseng D, Grimstad O, Naik H, Micheletti R, Guilbault S, **Miller AP**, **Hamzavi I**, van der Zee H, Prens E, Kappe N, Ardon C, Kirby B, Hughes R, Zouboulis C, Nikolakis G, Bechara FG, Matusiak L, Szepietowski J, Glowaczewska A, Smith SD, Goldfarb N, Daveluy S, Avgoustou C, Giamarellos-Bourboulis E, Cohen S, Soliman Y, Brant EG, Akilov O, Sayed C, Tan J, Alavi A, Lowes MA, Pascual JC, Riad H, Fisher S, Cohen A, Paek SY, Resnik B, Ju Q, Wang L, and Strunk A. Evaluating Patients' Unmet Needs in Hidradenitis Suppurativa: Results from the Global VOICE Project. *J Am Acad Dermatol* 2019; Epub ahead of print

PMID: 31279015 Epub ahead of print: July 2019

27. **Jahnke M**, and Kamat D. Neonatal Dermatology. *Pediatr Ann* 2019; 48(1):e9-e10.

PMID: 30653636 Pub:Jan 2019

1. Feinstein JA, Jambal P, Peoples K, Lucky AW, Khuu P, Tang JY, Lara-Corrales I, Pope E, Wiss K, Hook KP, Levin LE, Morel KD, Paller AS, McCuaig CC, Powell J, Eichenfield LF, Price H, Levy ML, Schachner LA, Browning JC, Bayliss S, **Jahnke M, Shwayder T**, Glick SA, Bruckner AL. JAMA Dermatol. 2019 Feb 1;155(2):196-203. doi: 10.1001/jamadermatol.2018.4673.

PMID:30586139 Pub. Feb. 2019

1. **Jiang AJ**, and **Lim HW**. Phototherapy in the Evaluation and Management of Photodermatoses. Dermatologics Clinics 2019; Epub ahead of print: Oct. 2019

PMID:31753194 Pub: Oct. 2019

1. Blume-Peytavi U, Bagot M, Tennstedt D, Saint Aroman M, Stockfleth E, Zlotogorski A, Mengeaud V, Schmitt AM, Paul C, **Lim HW**, Georgescu V, Dreno B, and Nocera T. Dermatology today and tomorrow: from symptom control to targeted therapy *J Eur Acad Dermatol Venereol* 2019; 33 Suppl 1:3-36.

PMID: 30561009 Pub:Jan 2019

1. Elmets CA, Leonardi CL, Davis DMR, Gelfand JM, Lichten J, Mehta NN, Armstrong AW, Connor C, Cordoro KM, Elewski BE, Gordon KB, Gottlieb AB, Kaplan DH, Kavanaugh A, Kivelevitch D, Kiselica M, Korman NJ, Kroshinsky D, Lebwohl M, **Lim HW**, Paller AS, Parra SL, Pathy AL, Prater EF, Rupani R, Siegel M, Stoff B, Strober BE, Wong EB, Wu JJ, Hariharan V, Menter A. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities. J Am Acad Dermatol. 2019 Apr;80(4):1073-1113. doi:

10.1016/j.jaad.2018.11.058.

PMID: 30772097 Epub: Feb 2019

1. Menter A, Strober BE, Kaplan DH, Kivelevitch D, Prater EF, Stoff B, Armstrong AW, Connor C, Cordoro KM, Davis DMR, Elewski BE, Gelfand JM, Gordon KB, Gottlieb AB, Kavanaugh A, Kiselica M, Korman NJ, Kroshinsky D, Lebwohl M, Leonardi CL, Lichten J, **Lim HW**, Mehta NN, Paller AS, Parra SL, Pathy AL, Rupani RN, Siegel M, Wong EB, Wu JJ, Hariharan V, Elmets CA. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019 Apr;80(4):1029-1072. doi: 10.1016/j.jaad.2018.11.057.

PMID: 30772098 Epub: Feb. 2019

1. Wang, SQ, **Lim, HW**. US Food and Drug Administration 2019 Proposed Rule On Sunscreens: Summary and Consequences. J Am Acad Dermatol 2019 Apr 4.

PMID:30954585 Epub ahead of print: April 2019

1. Elmets CA, **Lim HW**, Stoff B, et al. Joint American Academy of Dermatology-National Psoriasis Foundation Guidelines of Care for the Management and Treatment of Psoriasis with Phototherapy. *J Am Acad Dermatol* 2019; 81(3):775-804.

PMID: 31351884. Pub: July 2019

1. Burns EM, Ahmed H, Isedeh PN, **Kohli I**, Van Der Pol W, Shaheen A, Muzaffar AF, Al-Sadek C, Foy TM, Abdelgawwad MS, Huda S, **Lim HW**, **Hamzavi I**, Bae S, Morrow CD, Elmets CA, and Yusuf N. Ultraviolet radiation, both UVA and UVB, influences the composition of the skin microbiome *Exp Dermatol* 2019; 28(2):136-141.

PMID: 30506967 Epub ahead of print: Jan 2019

1. **Luther C, Lim HW.** Solar Angioedema: A report of a patient and a review of literature. Photodermatology Photoimmunol Photomed. 2019 May;35(3):187-189. [2018 Dec 5 Epub ahead of print]

PMID: 30520169 Epub ahead of print: Jan 2019

1. **Luther C**, Swami U, Zhang J, Milhem M, and Zakharia Y. Advanced stage melanoma therapies: Detailing the present and exploring the future. Crit Rev Oncol Hematol 2019; 133:99-111.

38. PMID: 30661664 Epub ahead of print: Nov. 2018

1. Li X, Darby J, **Lyons AB**, Woods GM et al. TNF May Negatively Regulate Phocytosis of Devil Facial Tumor Disease Cell by Activated Macrophages. Immunol Invest. Jan 2019

PMID: 30663448 Epub ahead of print:Jan 2019

1. Ong CEB, **Lyons AB**, Woods GM, Flies AS. Inducible IFN-y Expression for MHC-I Upregulation in Devil Facial Tumor Cells. Front Immunol. Jan. 2019

PMID:30692995 Epub ahead of print:Jan 2019

1. **Lyons, AB**, Peacock, A, Zubair, R, Lim, HW. Successful Treatment of Solar Urticaria with UVA1 Hardening in Three Patients. Photodermatol Photoimmunol Photomed, 2019 May;35(3):193-19

PMID: 30576021 Epub ahead of print:Jan 2019

1. **Lyons AB**, **Kohli I**, **Lim HW**, and **Hamzavi IH**. Insights on an in vivo model for postinflammatory hyperpigmentation *Br J Dermatol* 2019; Epub ahead of print

PMID: 30729515 Epub ahead of print:May2019

1. **Lyons AB**, **Zubair R**, **Kohli I**, and **Hamzavi IH**. Preoperative Ultrasound for Evaluation of Hidradenitis Suppurativa Dermatol Surg 2019; 45(2):294-296.

PMID: 30726198 Pub. Feb. 2019

1. **Lyons AB, Parks-Miller A, Zubair R, Hamzavi IH**. Ertapenem-a potent treatment for clinical and quality of life improvement in patients with hidradenitis suppurativa – Reply. Int J Dermatol April 2019

PMID: 30515760 Epub ahead of print:Dec 2018

1. **Lyons AB**, **Peacock A**, **Zubair R**, **Hamzavi IH**, and **Lim HW**. Successful treatment of solar urticaria with UVA1 hardening in three patients *Photodermatol Photoimmunol Photomed* 2019; 35(3):193-195.

PMID: 30576021 Epub ahead of print:Jan 2019

1. **Lyons AB**, Abbas Z, **Mohammad TF**, and **Hamzavi IH**. Use of Autologous, Noncultured Melanocyte-Keratinocyte Transplantation in Patients With Stable Genital Leucoderma. *Dermatol Surg* 2019; Epub ahead of print

PMID: 31343442 Epub ahead of print:July 2019

1. Kohli I, Nicholson CL, Williams JD, **Lyons AB**, Seo I, Maitra P, Tian X, Atillasoy E, **Lim HW**, and **Hamzavi IH**. Greater efficacy of SPF 100+ sunscreen compared to SPF 50+ in sunburnprevention during five consecutive days of sunlight exposure: A Randomized, Double-Blind Clinical Trial. *J Am Acad Dermatol* 2019;

PMID: 31542406 Epub ahead of print.Sept. 2019

1. **Lyons AB**, Moy L, Moy R and Tung R. Circadian rhythm and the skin: A review of the literature. J Clin Aesthet Dermatol 2019; (12(9):42-45.

PMID:31641418 Epub ahead of print:Jan 2019

1. **Lyons AB**, Peacock A, **Braunberger TL**, **Viola KV**, and **Ozog DM**. Disease Severity and Quality of Life Outcome Measurements in Patients With Keloids: A Systematic Review. *Dermatol Surg* 2019; Epub ahead of print.

PMID: 31567612 Epub ahead of print: Dec 2019

1. Turk D, Vellaichamy G, **Lyons AB**, **Parks-Miller A**, Nelson T, **Meysami A**, and **Hamzavi IH**. Anti-tumor necrosis factor (TNF)-induced lupus in a patient with hidradenitis suppurativa. *Int J Dermatol* 2019;

PMID: 31633193 Epub ahead of print.: Oct. 2019

1. **Lyons AB**, Townsend SM, Turk D, **Narla S**, Baah N, and **Hamzavi IH**. Laser and Light-Based Treatment Modalities for the Management of Hidradenitis Suppurativa. *Am J Clin Dermatol* 2019;

PMID: 31845121 Epub ahead of print:Dec 2019

1. Teran VA, **McHargue C**, and Gru AA. Photodistributed Rash Progressing to Erythroderma: Challenge *Am J Dermatopathol* 2019;

PMID: 30946096 Epub ahead of print:Mar 2019

1. Gru AA, **McHargue C**, and Salavaggione AL. A Systematic Approach to the Cutaneous Lymphoid Infiltrates: A Clinical, Morphologic, and Immunophenotypic Evaluation. *Arch Pathol Lab Med* 2019; 143(8):958-979.

PMID: 31339758 Epub ahead of print:Aug 2019

1. Mehta C, **Mohammad T**, Mehta D, **Griffith J**, Nicholson C, and **Hamzavi I**. Effect of Combination NSAID and NBUVB treatment in Non-Photoadapters - A Pilot Study *Photodermatol Photoimmunol Photomed* 2019;

PMID: 31004553 Epub ahead of print May 2019

1. Adelman M, **Mohammad T**, and **Kerr H**. Allergic Contact Dermatitis Due to Benzoyl Peroxide From an Unlikely Source *Dermatitis* 2019; 30(3):230-231.

PMID: 31045933 Pub:May 2019

1. Cole D, **Mohammed T**, and **Lim H**. Rapid Response of Pityriasis Rubra Pilaris with Psoriasis Overlap to Secukinumab. *Br J Dermatol* 2019; Epub ahead of print

PMID: 31260082 EPub ahead of print: Aug 2019

1. Mohammad TF, Kohli I, Nicholson CL, Treyger G. Chaowattanapanit S, Nahhas AF, Braunberger TL, Lim HW, Hamzavi IH. Oral Polypodium Leucotomos Extract and Its Impact on Visible Light-Induced Pigmentation in Human Subjects.

PMID: 31859468 Pub. Dec. 2019

1. **Narla S**, and **Lim HW**. Sunscreen: FDA regulation, and environmental and health impact. *Photochem Photobiol Sci* 2019;

PMID: 31845952 Pub: Jan 2020

1. **Oberlin DM**, **Porto DA**, **LoPiccolo MC**, and **Kohen LL**. Modified-purse-string closure: A lymphatic channel and tissue sparing technique for biopsy of suspicious pigmented lesions on extremities *J Am Acad Dermatol* 2019; 80(2):e33-e34.

PMID: 29505864 EPub ahead of print: Mar 2018

1. **Oberlin D**, Veenstra J, Zarbo A, Kerr H. Seeing a Difference: Assessment of a Visual Aid Toll for

Topical Medicaton Selection.. Am J Med Qual. 2019 Aug 28: Epub ahead of print]

PMID:31462058 Epub ahead of print:Aug 2019

1. Smith M, **Oberlin D**, Ozog D. **Under Pressure: Optimizing Intralesional Keloid Injections**.

Archives of Surgical Dermatology 2(1):21-22. Publish Date: February 2019

PMID: Not Assigned Pub: Feb 2019

1. **Oberlin D**, Lynam K, and **Douglass M**. Granulomatous reaction to autologous gluteal fat transfer. *JAAD Case Rep* 2019; 5(6):522-524.

PMID: 31205995 Epub ahead of print:June 2019

1. Riyaz FR, **Ozog DM**, and Dover JS. Managing and Reducing Office Expenses in Dermatology Surgery. *Dermatol Surg* 2019; Epub ahead of print.

PMID: 31449081 Epub ahead of print:Aug 2019

1. Saleh J, **Ozog DM**, Chitale DA, Friedman BJ. Ecchymotic Nodule on the Scalp: Challenge. Am J. Dermatopathology, 2019 Aug; 41(8)

PMID:31335426 Pub:Aug 2019

1. Saleh J, **Ozog DM**, **Chitale DA**, and **Friedman BJ**. Ecchymotic Nodule on the Scalp: Answer. *Am J Dermatopathol* 2019; 41(8):612-613.

PMID: 31335419 Pub:Aug 2019

1. Worley B, Owen JL, Barker CA, Behshad R, Bichakjian CK, Bolotin D, Bordeaux JS, Bradshaw S, Cartee TV, Chandra S, Cho N, Choi J, Council ML, Eisen DB, Golda N, Huang CC, Ibrahim SF, Jiang SIB, Kim J, Lacutoure M, Lawrence N, Lee EH, Leitenberger JJ, Maher IA, Mann M, Minkis K, Mittal B, Nehal KS, Neuhaus I, **Ozog DM**, Petersen B, Samie F, Shin TM, Sobanko JF, Somani AK, Stebbins WG, Thomas JR, Thomas V, Tse D, Waldman A, Xu YG, Yu SS, Zeitouni NC, Ramsay T, Poon E, and Murad A. Evidence-Based Clinical Practice Guidelines for Microcystic Adnexal Carcinoma: Informed by a Systematic Review. *JAMA Dermatol* 2019;

Epub ahead of print

PMID: 31268498 EPub ahead of print:July 2019

1. Owen JL, Kibbi N, Worley B, Kelm RC, Wang JV, Barker CA, Behshad R, Bichakjian CK, Bolotin D, Bordeaux JS,Bradshaw SH, Cartee TV, Chandra S, Cho NL, Choi JN, Council ML, Demirci H, Eisen DB, Esmaeli B, Golda N,Huang CC, Ibrahim SF, Jiang SB, Kim J, Kuzel TM, Lai SY, Lawrence N, Lee EH, Leitenberger JJ, Maher IA, Mann
2. MW, Minkis K, Mittal BB, Nehal KS, Neuhaus IM, **Ozog DM**, Petersen B, Rotemberg V, Samant S, Samie FH,Servaes S, Shields CL, Shin TM, Sobanko JF, Somani AK, Stebbins WG, Thomas JR, Thomas VD, Tse DT,Waldman AH, Wong MK, Xu YG, Yu SS, Zeitouni NC, Ramsay T, Reynolds KA, Poon E, and Alam M. Sebaceous
3. carcinoma: evidence-based clinical practice guidelines. *Lancet Oncol* 2019; 20(12):e699-e714.

PMID: 31797796 EPub ahead of print: Dec. 2019

1. Seago M, Shumaker PR, Spring LK, Alam M, Al-Niaimi F, Rox Anderson R, Artzi O, Bayat A, Cassuto D, Chan HH, Dierickx C, Donelan M, Gauglitz GG, Leo Goo B, Goodman GJ, Gurtner G, Haedersdal M, Krakowski AC, Manuskiatti W, Norbury WB, Ogawa R, **Ozog DM**, Paasch U, Victor Ross E, Tretti Clementoni M, and Waibel J. Laser Treatment of Traumatic Scars and Contractures: 2020 International Consensus Recommendations. *Lasers*

*Surg Med* 2019; Epub ahead of print.

PMID: 31820478 EPub ahead of print: Dec. 2019

1. Evans NS, **Pritchett EN**, Jones K, Doyle A, Chung CL, Allen HB, and Cusack CAR. Cutaneous gummatous tuberculosis in a kidney transplant patient *Cutis* 2018; 102(2):E32-E35.

PMID: 30893397 Pub:Feb 2019

1. **Schneider SL**, and **Lim HW**. Review of environmental effects of oxybenzone and other sunscreen active ingredients *J Am Acad Dermatol* 2019; 80(1):266-271.

PMID: 29981751 Epub ahead of print:Nov 2018

1. Siegel DR, **Schneider SL**, **Chaffins M**, and **Rambhatla PV**. A retrospective review of 93 cases of cellular dermatofibromas *Int J Dermatol* 2019;

PMID: 31074502 Epub ahead of print May 2019

1. Sharma A, Rozzelle A, Desai J, **Shwayder TA**, Kisseih E, Bryant JR, and Agarwal P. ABCA12 homozygous mutation in harlequin ichthyosis: Survival without systemic retinoids *Pediatr Dermatol* 2019; Epub ahead of print

PMID: 30809833 Epub ahead of print:Pub. Feb. 2019

1. Thanos A, **Shwayder T**, Papakostas TD, Corradetti G, Capone A, Jr., Sarraf D, Shields CL, and Trese MT. Retinal Vascular Abnormalities in Phakomatosis Pigmentovascularis. *Ophthalmol Retina* 2019;

PMID: 31420298. Epub ahead of Print July 2019

1. Elewski B, Alexis AF, Lebwohl M, **Gold LS**, Pariser D, Del Rosso J, and Yosipovitch G. Itch: An Under-recognized Problem in Psoriasis *J Eur Acad Dermatol Venereol* 2019; Epub ahead of print

PMID: 30680819 Epub ahead of print:Jan 2019

1. Lebwohl MG, Sugarman JL, **Gold LS**, Pariser DM, Lin T, Pillai R, Martin G, Harris S, and Israel R. Long-term safety results from a phase 3 open-label study of a fixed combination halobetasol propionate 0.01% and tazarotene 0.045% lotion in moderate-to-severe plaque psoriasis *J Am Acad Dermatol* 2019; 80(1):282-285.

PMID: 30227193. EPub ahead of print: Sept. 2018

1. **Gold LS**, Dhawan S, Weiss J, Draelos ZD, Ellman H, and Stuart IA. A novel topical minocycline foam for the treatment of moderate-to-severe acne vulgaris: Results of 2 randomized, double-blind, phase 3 studies *J Am Acad Dermatol* 2019; 80(1):168-177.

PMID: 30165171. Epub ahead of print: Aug 2018

1. Pariser DM, Kircik LH, and **Stein Gold LF**. Treating psoriasis: patient assessment, treatment goals, and treatment options *Cutis* 2019; 103(4s):S4-s7. 31045933

PMID: 31116804 Pub:Apr 2019

1. Kircik LH, **Stein Gold LF**, and Pariser DM. Improving Adherence to Topical Therapies Through Improved Clinician-Patient Communication and Shared Decision Making *Cutis* 2019; 103(4s):S13-s15.

PMID: 31116806. Pub:Apr 2019

1. Eichenfield LF, Del Rosso JQ, Tan JKL, Hebert AA, Webster GF, Harper J, Baldwin HE, Kircik LH, **Stein-Gold L**, Kaoukhov A, and Alvandi N. Use of an alternative method to evaluate erythemaseverity in a clinical trial: difference in vehicle response with evaluation of baseline and postdose photographs for effect of oxymetazoline cream 1.0% for persistent erythema of rosacea in a phase IV study *Br J Dermatol* 2019; 180(5):1050-1057.

PMID: 30500065 Epub ahead of print: Apr 2019

1. Tan J, Thiboutot D, Popp G, Gooderham M, Lynde C, Del Rosso J, Weiss J, Blume-Peytavi U, Weglovska J, Johnson S, Parish L, Witkowska D, Sanchez Colon N, Alio Saenz A, Ahmad F, Graeber M, and **Stein Gold L**. Randomized phase 3 evaluation of trifarotene 50 mug/g cream treatment of moderate facial and truncal acne. *J Am Acad Dermatol* 2019; 80(6):1691-1699.

PMID: 30802558 EPub ahead of print:Feb 2019

1. **Stein Gold LF**, Kircik LH, and Pariser DM. Understanding topical therapies for psoriasis *Cutis* 2019; 103(4s):S8-s12.

PMID: 31116805 EPub ahead of print: April 2019

1. **Stein Gold** L., An Under-Recognized Problem in Psoriasis. J Eru Acad Derm Venereol 2019; 33(8)1465-1476.

PMID:30680819 EPub ahead of print:May 2019

1. Callender VD, Alexis AF, **Stein Gold LF**, Lebwohl MG, Paller AS, Desai SR, Tan H, Ports WC, Zielinski MA, and Tallman AM. Efficacy and Safety of Crisaborole Ointment, 2%, for the Treatment of Mild-to-Moderate Atopic Dermatitis Across Racial and Ethnic Groups. *Am J Clin Dermatol* 2019; Epub ahead of print

PMID: 31264114. Pub:Oct 2019

1. Tanghetti EA, **Stein Gold L**, Del Rosso JQ, Lin T, Angel A, and Pillai R. Optimized formulation for topical application of a fixed combination halobetasol/tazarotene lotion using polymeric emulsion technology. *J Dermatolog Treat* 2019: 1-19;

PMID: 31522563 EPub ahead of print: Sept. 2019

1. Del Rosso JQ, Tanghetti E, Webster G, **Stein Gold L**, Thiboutot D, and Gallo RL. Update on the Management of Rosacea from the American Acne & Rosacea Society (AARS). J Clin Aesthet Dermatol 2019; 12(6):17-24.

PMID: 31360284 EPub ahead of print:June 2019

1. Schuler A, **Veenstra J, Ozog D**. Battling Neuropathic Scar Pain with Botulinum Toxin. J Drugs Dermatol. 2019 Sep 1l 18(9)937-938

PMID: 31524351 Pub:Sept. 2019

1. **Yeager DG, Lim HW**. What's New in Photoprotection: A Review of New Concepts and

Controversies. Dermatol Clin. 2019 Apr;37(2):149-157. doi: 10.1016/j.det.2018.11.003. Epub 2019 Feb 16. Review.

PMID: 30850037 Epub: Feb. 2019

1. Yeager Dg, et al. Update and Review of Bleeding Considerations in Dermatology Surgery: Anticoagulants and Antiplatelets. Dermatol Surg 2019. Epub ahead of print.

PMID: 31743247 Pub: Feb 2019

1. Yin C, et al Hyperuricaemia and Crystal-Associated Disease Network (G-CAN) consensus statement regarding labels and definitions of disease states of gout. Ann Rheum Dis. 2019

PMID 31501138 Epub ahead of print: Sept. 2019

1. **Zarbo A**, Inamdar K, **Friedman BJ**. Tender Nodules on the Extremities: Challenge. Am J Dermatopathology. July 2019

PMID: 31295159 EPub ahead of print: July 2019

1. **Zubair R**, **Lyons AB**, **Vellaichamy G**, Peacock A, and **Hamzavi I**. What's New in Pigmentary Disorders? *Dermatol Clin* 2019; Epub ahead of print

PMID: 30850040 EPub ahead of print: Feb 2019

94. Zubair R, and **Hamzavi IH**. Phototherapy for Vitiligo. *Dermatologic Clinics* 2019; Epub

PMID:31753192 EPub ahead of print: Oct. 2019

**Attachment 3 – Awards, Honors and Offices**

Roles in major offices and national organizations:

**Marsha Chaffins, MD**

* American Society of Dermatopathology Informatics Committee

**Iltefat Hamzavi, M.D.**

* Global Vitiligo Foundation (GVF)
* Hidradenitis Suppurativa Foundation (HSF)

**Richard Huggins, M.D.**

* Vitiligo Foundation

**Diane Jackson, M.D.**

* HFHS/Dept. of Dermatology Diversity Committee
* Skin of Color Society – Scientific and Membership Committee

**Marla Jahnke, MD**

* Society for Pediatric Dermatology – Workforce Committee
* Society for Pediatric Dermatology – Fellowship Director’s Committee
* American Academy of Dermatology – Patient Advocate Task Force
* Research PI – Epidermolysis Bullosa Research Partners
* Peds/Derm Course for HFHS/WSU Residents. 2/5,12,19, 2021
* American Contact Derm Society – Awards Committee
* Peds/Derm Course for HFHS/WSU Residents. 2/5/ 2021
* MDS Educational Content Committee (2020-Present)

**Henry Lim, M.D.**

* American Academy of Dermatology
	+ 1/19 – 1/21 Chair, Program Assessment Workgroup
	+ 3/19 – Present Chair, Ad Hoc Task Force on Sunscreens
	+ 4/19 – Present Member, Skin Cancer and Skin of Color Workgroup
	+ 11/19 Member, Skin of Color Curriculum Workgroup
* Peds/Derm Course for HFHS/WSU Residents. 2/5/ 2021
* International League of Dermatological Societies
	+ 2019 – Elected member, Board of Directors
	+ 9/2019 – Present Member of the Executive Committee
	+ 9/2019 – Present Chair of the 3rd ILDS World Skin Summit Programe Committee
	+ 9/2019 – Present Vice-Chair of the 2023 World Congress of Dermatology
	+ Scientific Programe Committee

**** 9/2019-Present Member of the Finance and Fundraising Committee

* + 11/2019-Present Member, WHO (World Health Organization) Committee
* Clarence S. Livingood Lectureship and Education Fund
	+ 7/1997 – Present Member, Board of Trustees
	+ 5/2008 – Present President

**Tasneem Mohammad, M.D.**

* 2015-Present Member, Global Vitiligo Foundation
* 2020-Present Global Vitiligo Foundation Committee

**David Ozog, M.D.**

* AAD Annual Meeting Chair Boston 2022
* American Society for Dermatologic Surgery – Member – three-year term
* AAD Scientific Assembly Committee 2016-2022
* ASDS Nominating Committee 2016-Present
* JAAD Editorial Board
* Derm Surgery Asst. Editor
* Lasers in Surgery and Medicine Editorial Board
* Amer Society of Derm Surgery:
* Task Force for Developing Cosmetic Training for Residents 2016-Present
* Nominating Committee
* Henry Ford Health System
* Chair’s Council 2016-Present
* Cultural Change Steering Committee – 2018-Present
* Advance Practice Provider Committee
* Operations Council 2011-Present
* WB Hospital Retail Services Committee
* Cosmetic Services Committee 2015-Present
* Developed Medical Student Lecture Series for Dermatology Rotators
* Visiting House Officer Education Coordinator – Dept of Dermatology

**Linda Stein, M.D.**

* Vice President American Academy of Dermatology 2020-2021
* National CME Chairperson
* Skin Disease Education Foundation Las Vegas Dermatology Meeting (yearly)
* Skin Disease Education Foundation Hawaii Dermatology Meeting (yearly)
* Women and Pediatrics Dermatology Meeting (yearly)
* Peds/Derm Course for HFHS/WSU Residents. 2/5,12,19, 2021

**AWARDS for the past three years:**

**Awards for 2021:**

**DERMATOLOGY RESIDENT GRADUATION – JUNE 2021Awards**

* E.A. Krull, MD Annual Faculty Role Model Award – Alison Boucher, MD
* Dermatology Resident Graduating Class Excellence in Patient Care Award-Anna Axelson, MD
* Margaret Douglass, M.D. Dedication to Dermatology Award – Ben Friedman

* Kathryn Quinlan, M.D. Devotion to Humanism Award – Aretha Bidden, MA

**Dr. Richard Huggins:**

* Nominated for a presidential citation from the AAD.

**Dr. Henry Lim:**

* Dr. Henry Lim honored as “Giant in Dermatology”, Inaugural Recipient
* Werthan Lecture Series Visiting Professor, Dept of Dermatology, Vanderbilt Univ.
* Top rated sunscreen expert in the world, based on publications 2011-2021. Expertscape. [https://expertscape.com/ex/sunscreening+agents](https://expertscape.com/ex/sunscreening%2Bagents)
* A top 20 author in dermatology (per the Journal of the American Academy of Dermatology) from 2010-2019 with more than 2,500 citations. (Szeto, MD, … Dellavalle, RP. J Am Acad Dermatol Dec 2021; 85:1573-1579).
* Honorary member, American Academy of Dermatology

**Dr. David Ozog:**

* PRESIDENTIAL AWARD FOR CONTIBUTIONS DURING COVID PANDEMIC American Society for Dermatologic Surgery
* PRESIDENTIAL AWARD American Society for Lasers in Medicine and Surgery

**Awards for 2020:**

**DERMATOLOGY RESIDENT GRADUATION – JUNE 2020 Awards**

* E.A. Krull, MD Annual Faculty Role Model Award – Dr. Veenstra 2019-20 - 6/2020
* Margaret Douglass, M.D. Dedication to Dermatology Award – 2020 Dr. Molly Powers
* Kathryn Quinlan, M.D. Devotion to Humanism Award – Richard Huggins, MD

**TOP DOCS -HOUR DETROIT MAGAZINE -Year 2020**

* Dr. Alison Boucher
* Dr. Iltefat Hamzavi
* Dr. Marla Jahnke
* Dr. Holly Kerr
* Dr. Laurie Kohen
* Dr. Jungho Kwon
* Dr. David Ozog
* Dr. Pranita Rambhatla
* Dr. Tor Shwayder
* Dr. Linda Stein

**Awards for 2019:**

**Pranita Rambhatla, MD**

Recipient of Academic Dermatology Leadership Program (ADLP). American Academy of Dermatology 2019-20.

Developed Student Department Lectures for Med Student/House Officer Rotators – Dept of Dermaotlogy.

**Henry W. Lim, M.D**.

Presidential Citation, American Academy of Dermatology, in recognition of your wisdom and support throughout my year as president. 2019

Recipient, International League of Dermatological Societies Certificate of Appreciation for

|  |  |
| --- | --- |
| International Leadership. | 2019 |

Honorary member, Mexican Academy of Dermatology (Academia Mexicana de Dermatologia,

AC). 2019

Alumni Achievement Award for Distinguished Service to American Medicine, College of

|  |  |
| --- | --- |
| Medicine, SUNY Downstate | 2019 |

Kathryn Quinlan, MD Devotion to Humanism Award, Dept of Dermatology, Henry Ford Hospital (selected by graduating residents) 2019

Recipient, International League of Dermatological Societies Certificate of Appreciation for

|  |  |
| --- | --- |
| International Leadership. | 2019 |

Finsen Medal, International Union of Photobiology (the fifth dermatologist selected for this award since it was first awarded in 1937)

**Dermatology/Resident Graduation – JUNE 2019 Awards**

* Kathryn Quinlan, M.D. Devotion to Humanism Award –Dr. Henry Lim
* Dermatology Resident Educator of the year – Dr. Ben Friedman
* Margaret Douglass, M.D. Award - Dr. Tor Shwayder

**Attachment 4 – Grants**

Qing-Sheng Mi

* **Federal-** B11243- NIH R33- Uncover the new subsets of epidermal Langerhans cells
* **Federal-** B11246- NIH R21- Genetic risk of hidradenitis suppurativa in African Americans
* **Federal-** B11247- NIH R56- Decoding TGF-beta signaling pathways in skin langerhans cells
* **Federal**- B40782- NIH R01 Subcontract- Genetic and Genomic Dissection of Psoriatic Arthritis
* **Federal**- B40836- NIH R01 Subcontract- Multi-racial genetic analysis of hidradenitis suppurativa

Li Zhou

* **Federal**- B11179- NIH R01 microRNAs Regulate Skin Langerhans Cells Jesse Veenstra
* **University-** F80009- MSU HSC Grant- Modulation of the Aryl Hydrocarbon Receptor by Adipose Tissue: Implications for Skin Carcinogenesis

David Ozog

* **Pharmaceutical-** E18205 Biofrontera, Protocol ALA-BCC-CT013- A randomized, double blind, vehicle-controlled multicenter phase III study to evaluate the safety and efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the treatment of superficial basal cell carcinoma (sBCC) with photodynamic therapy (PDT).
* **Pharmaceutical**- E19081- Galderma, The efficacy and molecular mechanism of Botulinum toxin in the reduction

of breast reduction mammaplasty scar formation: A prospective, controlled, randomized, double- blinded study

* **Pharmaceutical-** E21186- Vivosite, Laser treatment of basal cell carcinoma under imaging guidance

Richard Huggins

* **Pharmaceutical-** E21169- Incyte, Protocol INCB 18424-308- A Double-Blind, Vehicle-Controlled, Randomized Withdrawal and Treatment Extension Study to Assess the Long-Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo (TRuE-V LTE)

Linda Stein-Gold

* **Pharmaceutical**- E18157- Pfizer, Protocol B7451015- A phase 3 randomized, double-blind, multi-center, long-term extension study investigating the efficacy and safety of Pf-04965842, with or without topical medications, administered To subjects aged 12 years and older with moderate to severe

Atopic dermatitis

* **Pharmaceutical**- E18204- AbbVie, Protocol M16-045- M16-045: A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis
* **Pharmaceutical-** E18210- Novartis, Protocol CLYS006X2201- A randomized, subject and investigator blinded, placebo controlled, multi-center study in parallel groups to assess the efficacy and safety of LYS006 in patients with moderate to severe inflammatory acne
* **Pharmaceutical-** E20090- Arcutis, Protocol ARQ-151-302- A Phase 3, 8-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 0.3% Administered QD in Subjects with Chronic Plaque Psoriasis
* **Pharmaceutical-** E20122- Arcutis, Protocol ARQ-155-203- A Phase 2b, 8-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-154 Foam 0.3% Administered QD in Subjects with Seborrheic Dermatitis”, as amended from time to time
* **Pharmaceutical**- E20163- Dermira, Protocol DRM06-AD04- A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Lebrikizumab in Patients With Moderate-To-Severe Atopic Dermatitis
* **Pharmaceutical-** E20169- Arcutis, ARQ-252-205- A Phase 1/2b, Multiple Dose and 12-Week, Parallel Group,

Double Blind, Dose Ranging, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-252 Cream 0.1% and ARQ-252 Cream 0.3% in Subjects with Chronic Hand Eczema

* **Pharmaceutical**- E20171- Abbvie, Protocol M19-850- Atopic Dermatitis: Open-Label Extension Study of Upadacitinib in Adult Subjects with Moderate to Severe Atopic Dermatitis
* **Pharmaceutical-** E20172- Arcutis, Protocol ARQ-154-214- A Phase 2, Multicenter, Open-Label Study of the Long-Term Safety of ARQ-154 Foam 0.3% in Subjects with Seborrheic Dermatitis

* **Pharmaceutical**- E20192- Galderma, Protocol RD.06.SPR.118169- A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Subjects with Moderate to- Severe Atopic Dermatitis
* **Pharmaceutical**- E20240- Arcutis, Protocol ARQ-151-306- A Phase 3, Multicenter, Open-Label Extension Study of the Long-Term Safety of ARQ-151 Cream 0.3% in Subjects with Chronic Plaque Psoriasis.
* **Pharmaceutical-** E21026- Galderma, Protocol 118163- A Prospective, Multicenter, Long-Term Study to Assess the Safety and Efficacy of Nemolizumab (CD14152) in Subjects with Moderate-to-Severe Atopic Dermatitis
* **Pharmaceutical**- E21065- Abbvie, Protocol M15-994- IMMprint: A Phase 3b Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo Controlled Study Evaluating Safety and Efficacy of Risankizumab Compared to Placebo in Adult Subjects with Moderate to Severe Plaque Psoriasis with Palmoplantar (Non-Pustular) Involvement (PPPsO)
* **Pharmaceutical-** E21069- Pfizer, Protocol C3941002- a phase 2a, randomized, double blind, vehicle controlled, parallel group study to assess the efficacy, safety, tolerability and pharmacokinetics of pf-07038124 ointment for 6 weeks in participants with mild to moderate atopic dermatitis or plaque psoriasis
* **Pharmaceutical**- E21089- UCB Biopharma, Protocol UBC PS0007- Multicenter, randomized, parallel-group, double-blind, placebo-controlled (12-17 years) including a single open-label arm (6-11 years) study to evaluate the efficacy, safety, and pharmacokinetics of certolizumab pegol (czp) in pediatric study participants with moderate to severe chronic plaque psoriasis (pso)
* **Pharmaceutical**- E21099- Dermira, Protocol DRM06-AD07- A long-term study to assess the safety and efficacy of lebrikizumab in patients with moderate-to-severe atopic dermatitis
* **Pharmaceutical**- E21145- Arcutis, Protocol ARQ-151-311- A Phase 3, 4-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 0.15% Administered QD in Subjects with Atopic Dermatitis
* **Pharmaceutical**- E21154- AnaptysBio, Protocol ANB019-209- A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Subjects with Acne Vulgaris

* **Pharmaceutical-** E21171- Amgen, Protocol 2190194- A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-Ranging, Phase 2b Study to Evaluate Efficacy and Safety of Tezepelumab for the Treatment of Chronic Spontaneous Urticaria
* **Pharmaceutical-** E21172- Arcutis, Protocol ARQ-151-313- A Phase 3, Multicenter, Open-Label Extension Study of the Long-Term Safety of ARQ-151 Cream 0.15% and ARQ-151 Cream 0.05% in Subjects with Atopic Dermatitis
* **Pharmaceutical-** E21189- Arcutis, Protocol ARQ-154-304- A Phase 3, 8-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-154 Foam 0.3% Administered QD in Subjects with Seborrheic Dermatitis
* **Pharmaceutical-** E21198- Abbvie, Protocol M20-326- Plaque Psoriasis: A Phase 4 Multicenter, Randomized, Open-label, Efficacy Assessor-blinded-Study of Risankizumab Compared to Apremilast for the

Treatment of Adult Subjects with Moderate Plaque Psoriasis who are Candidates for Systemic Therapy

* **Pharmaceutical-** E22010- Arcutis, Protocol ARQ-154-309- A Phase 3, 8-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-154 Foam 0.3% Administered QD in Subjects with Scalp and Body Psoriasis (ARRECTOR)
* **Pharmaceutical**- E22020- Dermata Therapeutics, Protocol DMT310-005- A study of the tolerability, safety, and efficacy of dmt310 for the treatment of acne rosacea
* **Pharmaceutical**- E22021- Dermavant Sciences, Protocol DMVT-505-3102- An Open-Label, Long-Term Extension Study to Evaluate the Safety and Efficacy of Tapinarof Cream 1% in Subjects with Atopic Dermatitis
* **Pharmaceutical**- E22030- Incyte, Protocol INCB-18424-305- A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Children (Ages ≥ 2 Years to < 12

Years) With Atopic Dermatitis

* **Pharmaceutical**- E22072- Amgen, Protocol 20200497- A Multicenter, Randomized, Double-blind Study Evaluating the Pharmacokinetics, Efficacy, Safety, and Immunogenicity of Multiple Switches Between Humira® (adalimumab [US]) and ABP 501 Compared With Continued Use of Adalimumab in Subjects With Moderate to Severe Plaque Psoriasis

* **Pharmaceutical**- E22074- Galderma, Protocol 118126- A Multicenter, Open-Label, Single-Group Clinical Trial to Assess the Pharmacokinetics, Safety and Efficacy of Nemolizumab (CD14152) in Pediatric Subjects (aged 2 to 11 years) with Moderate-to-Severe Atopic Dermatitis
* **Pharmaceutical**- E22108- Dermavant Sciences, Protocol DMVT-505-3103- An Open-Label, Long-Term Extension Study to Evaluate the Safety and Efficacy of Tapinarof Cream 1% in Subjects with Atopic Dermatitis

Tasneem Mohammad

* **Pharmaceutical-** E22107- Clinuval, Protocol CUV104- An Open Label, Phase II Study to Assess the Changes in Pigmentation and Safety of Subcutaneous, Bioresorbable Afamelanotide Implants in the Treatment of Vitiligo on the Face
* **Pharmaceutical**- E22111- Unigen, The effect of a topical antioxidant product on skin lightening

Indermeet Kohli

* **Foundation-** F11139- Dermatology Foundation, Optimizing Phototesting and Investigating Photobiology of Visible Light

Iltefat Hamzavi

* **Federal-** B45253- Immune Tolerance Network Fixed Price, Protocol ITN086AI, Evaluation of AMG 714 for Vitiligo: A Phase 2a Randomized Double Blind Placebo Controlled Trial
* **Pharmaceutical**- E21084- Avita, Protocol CTP009- A Prospective Multi-Arm Blinded Evaluator Within-Subject Randomized Controlled Clinical Study to Investigate the Safety and Effectiveness of RECELL for Re-pigmentation of Stable Vitiligo Lesions
* **Pharmaceutical-** E22117- Pfizer SOCS- Advancing Research Knowledge and improving Health Outcomes of Skin of Color Patients
* **Foundation**- F11149- HS Foundation, Danby Grant- The effect of diet and nutrition on inflammation in

Hidradenitis Suppurativa.

* **Foundation**- H10336- Abbvie Research Fellowship- Henry Ford Dermatology Research Fellowship

Henry Lim

* **Federal**- F11098- PCORI Lite- A pragmatic trial of home versus office based narrow band ultraviolet B phototherapy for the treatment of psoriasis

.

Attachment 5 - Assurances

CHM Assurances in Response to Dean Amalfitano’s Concerns

Submitted to CAC October 17, 2022

On Friday, October 14, Dean Amalfitano sent the email copied below in response to the CHM submissions for Departments of Neurosurgery and Urology. To help clarify our response to the questions, we have inserted bold numbers before the questions. Our responses follow the email.

“Afternoon Aron, Nara, Carol, and members of the CHM CAC. I have also cc’ed Dr. David Kaufman, Asst.VP of Clinical Affairs in the Office of Health Sciences, as there are clinical implications related to the new department request(s) , as noted below.

We again appreciate the opportunity to participate in the “assurances” portion of your processes. We have had several questions and suggestions generally arise in regard to the proposed departments, which I’ve again pasted below for your team’s consideration.

**[1]**Questions as to adding these departments (some of which are clearly duplicative of existing depts/divisions-with vague plans as to how to reconcile these duplications in the future) will create confusion as to which departments are East Lansing based, vs Providence based, vs HF based, and where faculty will be residing primarily, in particular when initially responding to job postings etc. **[2]** This also touches on referral pattern confusion, for example if we have Neurosurgeons/Spine Surgeons in the COM Osteopathic Surgical and Orthopedic Specialties depts at MSU-HCI in East Lansing, yet there is another “Neurosurg” dept, practicing in South East Michigan, and another at Providence Hospital as well.

[Variation for the urology proposal also emailed on October 14, “This also touches on referral pattern confusion, for example if we have Urologists in the COM Osteopathic Surgical Specialties dept at MSU-HCI in East Lansing, yet there is another Urology dept, practicing in South East Michigan.”]

[Variation for the Dermatology proposal emailed by Dean Amalfitano on September 19, 2022, “Morning Aron, and members of the CHM CAC.

We appreciate the opportunity to participate in the “assurances” portion of your processes. We have had several questions and suggestions generally arise in regard to the proposed 4 new departments, which I’ve basically pasted below for your team’s consideration. Thank you. AA

This also touches on referral pattern confusion, for example if we have ENT’s at MSU-HCI in East Lansing, yet there is another ENT dept, practicing in South East Michigan.”]

1. Will any research done by the no-cost faculty becoming part of these depts., be attributed to MSU generally, MSU CHM or strictly to the jointly funded Health Sciences Center at Henry Ford?. **[4]** Will future investments in research faculty be shared across colleges, should they reside in a HF located dept?
2. In line with the above, a general theme is questioning why these departments, and the faculty assigned to them, could not be shared between the medical schools, just as several other departments already are. We note that in the creation of the most recent dept on the MSU East Lansing campus., the Dept. of Orthopedics, this premise was highly desired by both colleges, and indeed the current Dept of Orthopedics is shared between COM and CHM.

1. Is there a mechanism or plan for clinically active HF faculty to also be appointed through the

MSU HCI?

1. We are concerned with the lack of acknowledgement of COM education or role in some of these proposed new departments. For example, it is critical that the new Urology dept. chair recognize two completely different educational approaches in CHM and COM and joint appointments might be considered to recognize these dichotomies, especially as both COM and CHM students are being trained currently at Henry Ford System hospitals.

Thank you for your thoughtful consideration of these comments and questions.

AA”

-----------

The College of Human Medicine responds:

As to [1]

It is true that we have some existing divisions (e.g., Neurosurgery *division which is* not a *department*). Divisions are constructs of the dean’s office and are not recognized by the university. Our proposal here is to create statewide departments, as all CHM departments are. In general, if there are existing divisions, structurally these will be incorporated into the appropriate departments either as a sub-entity or as a merger (depending on faculty needs and wishes). It is true that some departments have more faculty based in East Lansing (e.g., Medicine) or Grand Rapids (e.g., Pediatrics and Emergency Medicine), but that does not define the department, and faculty from all over the state can be in the department. It is also true that the collaborations in each department can be complex, but all departments in the university that engage with the community deal with complexity at some level. The college does not specify where faculty have to live as long as they can fulfill their role. Also note, we are purposely not creating duplicative departments.

As to [2]

Inclusion in MSU HealthCare, Inc. practices (and referrals to MSU physicians) is a separate issue than membership in a department. In this sense, these new departments will be the same as existing departments that include non-HCI faculty, including non-prefix faculty, from Flint, Grand Rapids, Detroit, the Upper Peninsula, or other communities across Michigan. Clinical integration partnerships between MSU and hospital systems, including joint ventures in radiology, or non-clinical relationships, including a statewide residency consortium, create more areas for confusion than these departments will. As a particular example, the neurosurgeons based at Ascension Providence are faculty for both CHM and COM, yet both colleges have decided that any confusion clinically is tolerable given the benefits to students.

As to [3]

The creation of this department will not change the eventual attribution of research funding. As a matter separate from the creation of these departments, we believe MSU, the Health Science Center, applicable college and department will all have attribution, but that system has not been implemented.

As to [4]

Investments from the college to departments will continue as they have for all departments, whether they are joint or in a single college. The attribution and indirect costs follow the appointments and investments as they do now, regardless of the geographical location of the department. For example, for departments located in Grand Rapids and Flint and invested in by CHM- research attribution and indirect costs will flow through CHM. Similarly, for departments located in East Lansing and jointly invested by COM- research attribution and indirect costs flow through the respective college in which the faculty is appointed. CHM has no interest in overturning the current system.

As to [5]

Neither the College of Human Medicine nor the collaborating physicians at Henry Ford Health envision these as joint departments. Some joint departments have been successful, but they are more difficult to administer. The orthopedics department is an interesting example, because administration of that unit has been a challenge and not an experience to be replicated. As in all of our departments, we will welcome faculty from other departments and colleges who are interested in secondary appointments in the new departments.

As to [6]

As of October 16, 2022, there is no pathway for Henry Ford Medical Group faculty to be appointed in MSU HeathCare, Inc., and any decisions to create such a pathway are separate from the department decisions. This is analogous to the CHM Emergency Medicine department created a decade ago; faculty employed by ECS are not “appointed” or credentialed in MSU HCI.

As to [7]

We expect the new department will only increase options available to COM students. The college and the new department are open to cross-listing classes as happens now across the university, and we will ensure the courses of the new department will be available to medical students regardless of college. Finally, there is nothing in the creation of the department that disturbs the existing curricular courses used by COM students. In fact, these additional departments enhance research, educational and clinical opportunities for COM students.